6	VICTRELIS.xml:S1:4:1	O
ADVERSE	VICTRELIS.xml:S1:6:7	O
REACTIONS	VICTRELIS.xml:S1:14:9	O

See	VICTRELIS.xml:S1:27:3	O
the	VICTRELIS.xml:S1:31:3	O
peginterferon	VICTRELIS.xml:S1:35:13	O
alfa	VICTRELIS.xml:S1:49:4	O
and	VICTRELIS.xml:S1:54:3	O
ribavirin	VICTRELIS.xml:S1:58:9	O
prescribing	VICTRELIS.xml:S1:68:11	O
information	VICTRELIS.xml:S1:80:11	O
for	VICTRELIS.xml:S1:92:3	O
description	VICTRELIS.xml:S1:96:11	O
of	VICTRELIS.xml:S1:108:2	O
adverse	VICTRELIS.xml:S1:111:7	O
reactions	VICTRELIS.xml:S1:119:9	O
associated	VICTRELIS.xml:S1:129:10	O
with	VICTRELIS.xml:S1:140:4	O
their	VICTRELIS.xml:S1:145:5	O
use	VICTRELIS.xml:S1:151:3	O
.	VICTRELIS.xml:S1:154:1	O

EXCERPT	VICTRELIS.xml:S1:162:7	O
:	VICTRELIS.xml:S1:169:1	O
The	VICTRELIS.xml:S1:173:3	O
most	VICTRELIS.xml:S1:177:4	O
commonly	VICTRELIS.xml:S1:182:8	O
reported	VICTRELIS.xml:S1:191:8	O
adverse	VICTRELIS.xml:S1:200:7	O
reactions	VICTRELIS.xml:S1:208:9	O
(	VICTRELIS.xml:S1:218:1	O
greater	VICTRELIS.xml:S1:219:7	O
than	VICTRELIS.xml:S1:227:4	O
35%	VICTRELIS.xml:S1:232:3	O
of	VICTRELIS.xml:S1:236:2	O
subjects	VICTRELIS.xml:S1:239:8	O
)	VICTRELIS.xml:S1:247:1	O
in	VICTRELIS.xml:S1:249:2	O
clinical	VICTRELIS.xml:S1:252:8	O
trials	VICTRELIS.xml:S1:261:6	O
in	VICTRELIS.xml:S1:268:2	O
adult	VICTRELIS.xml:S1:271:5	O
subjects	VICTRELIS.xml:S1:277:8	O
receiving	VICTRELIS.xml:S1:286:9	O
the	VICTRELIS.xml:S1:296:3	O
combination	VICTRELIS.xml:S1:300:11	O
of	VICTRELIS.xml:S1:312:2	O
VICTRELIS	VICTRELIS.xml:S1:315:9	O
with	VICTRELIS.xml:S1:325:4	O
PegIntron	VICTRELIS.xml:S1:330:9	O
and	VICTRELIS.xml:S1:340:3	O
REBETOL	VICTRELIS.xml:S1:344:7	O
were	VICTRELIS.xml:S1:352:4	O
fatigue	VICTRELIS.xml:S1:357:7	B-AdverseReaction
,	VICTRELIS.xml:S1:364:1	O
anemia	VICTRELIS.xml:S1:366:6	B-AdverseReaction
,	VICTRELIS.xml:S1:372:1	O
nausea	VICTRELIS.xml:S1:374:6	B-AdverseReaction
,	VICTRELIS.xml:S1:380:1	O
headache	VICTRELIS.xml:S1:382:8	B-AdverseReaction
and	VICTRELIS.xml:S1:391:3	O
dysgeusia	VICTRELIS.xml:S1:395:9	B-AdverseReaction
.	VICTRELIS.xml:S1:404:1	O

(	VICTRELIS.xml:S1:406:1	O
6.1	VICTRELIS.xml:S1:409:3	O
)	VICTRELIS.xml:S1:414:1	O

To	VICTRELIS.xml:S1:422:2	O
report	VICTRELIS.xml:S1:425:6	O
SUSPECTED	VICTRELIS.xml:S1:432:9	O
ADVERSE	VICTRELIS.xml:S1:442:7	O
REACTIONS	VICTRELIS.xml:S1:450:9	O
,	VICTRELIS.xml:S1:459:1	O
contact	VICTRELIS.xml:S1:461:7	O
Merck	VICTRELIS.xml:S1:469:5	O
Sharp	VICTRELIS.xml:S1:475:5	O
Dohme	VICTRELIS.xml:S1:483:5	O
Corp	VICTRELIS.xml:S1:489:4	O
.	VICTRELIS.xml:S1:493:1	O
,	VICTRELIS.xml:S1:494:1	O
a	VICTRELIS.xml:S1:496:1	O
subsidiary	VICTRELIS.xml:S1:498:10	O
of	VICTRELIS.xml:S1:509:2	O
Merck	VICTRELIS.xml:S1:512:5	O
Co	VICTRELIS.xml:S1:520:2	O
.	VICTRELIS.xml:S1:522:1	O
,	VICTRELIS.xml:S1:523:1	O
Inc	VICTRELIS.xml:S1:525:3	O
.	VICTRELIS.xml:S1:528:1	O
,	VICTRELIS.xml:S1:529:1	O
at	VICTRELIS.xml:S1:531:2	O
1	VICTRELIS.xml:S1:534:1	O
-	VICTRELIS.xml:S1:535:1	O
877	VICTRELIS.xml:S1:536:3	O
-	VICTRELIS.xml:S1:539:1	O
888	VICTRELIS.xml:S1:540:3	O
-	VICTRELIS.xml:S1:543:1	O
4231	VICTRELIS.xml:S1:544:4	O
or	VICTRELIS.xml:S1:549:2	O
FDA	VICTRELIS.xml:S1:552:3	O
at	VICTRELIS.xml:S1:556:2	O
1	VICTRELIS.xml:S1:559:1	O
-	VICTRELIS.xml:S1:560:1	O
800	VICTRELIS.xml:S1:561:3	O
-	VICTRELIS.xml:S1:564:1	O
FDA	VICTRELIS.xml:S1:565:3	O
-	VICTRELIS.xml:S1:568:1	O
1088	VICTRELIS.xml:S1:569:4	O
or	VICTRELIS.xml:S1:574:2	O
www	VICTRELIS.xml:S1:582:3	O
.	VICTRELIS.xml:S1:585:1	O
fda	VICTRELIS.xml:S1:586:3	O
.	VICTRELIS.xml:S1:589:1	O
gov	VICTRELIS.xml:S1:590:3	O
medwatch	VICTRELIS.xml:S1:594:8	O
.	VICTRELIS.xml:S1:604:1	O

6.1	VICTRELIS.xml:S1:616:3	O

Clinical	VICTRELIS.xml:S1:620:8	O
Trials	VICTRELIS.xml:S1:629:6	O
Experience	VICTRELIS.xml:S1:636:10	O

Because	VICTRELIS.xml:S1:650:7	O
clinical	VICTRELIS.xml:S1:658:8	O
trials	VICTRELIS.xml:S1:667:6	O
are	VICTRELIS.xml:S1:674:3	O
conducted	VICTRELIS.xml:S1:678:9	O
under	VICTRELIS.xml:S1:688:5	O
widely	VICTRELIS.xml:S1:694:6	O
varying	VICTRELIS.xml:S1:701:7	O
conditions	VICTRELIS.xml:S1:709:10	O
,	VICTRELIS.xml:S1:719:1	O
adverse	VICTRELIS.xml:S1:721:7	O
reaction	VICTRELIS.xml:S1:729:8	O
rates	VICTRELIS.xml:S1:738:5	O
observed	VICTRELIS.xml:S1:744:8	O
in	VICTRELIS.xml:S1:753:2	O
clinical	VICTRELIS.xml:S1:756:8	O
trials	VICTRELIS.xml:S1:765:6	O
of	VICTRELIS.xml:S1:772:2	O
VICTRELIS	VICTRELIS.xml:S1:775:9	O
cannot	VICTRELIS.xml:S1:785:6	O
be	VICTRELIS.xml:S1:792:2	O
directly	VICTRELIS.xml:S1:795:8	O
compared	VICTRELIS.xml:S1:804:8	O
to	VICTRELIS.xml:S1:813:2	O
rates	VICTRELIS.xml:S1:816:5	O
in	VICTRELIS.xml:S1:822:2	O
the	VICTRELIS.xml:S1:825:3	O
clinical	VICTRELIS.xml:S1:829:8	O
trials	VICTRELIS.xml:S1:838:6	O
of	VICTRELIS.xml:S1:845:2	O
another	VICTRELIS.xml:S1:848:7	O
drug	VICTRELIS.xml:S1:856:4	O
and	VICTRELIS.xml:S1:861:3	O
may	VICTRELIS.xml:S1:865:3	O
not	VICTRELIS.xml:S1:869:3	O
reflect	VICTRELIS.xml:S1:873:7	O
the	VICTRELIS.xml:S1:881:3	O
rates	VICTRELIS.xml:S1:885:5	O
observed	VICTRELIS.xml:S1:891:8	O
in	VICTRELIS.xml:S1:900:2	O
practice	VICTRELIS.xml:S1:903:8	O
.	VICTRELIS.xml:S1:911:1	O

The	VICTRELIS.xml:S1:917:3	O
following	VICTRELIS.xml:S1:921:9	O
serious	VICTRELIS.xml:S1:931:7	O
and	VICTRELIS.xml:S1:939:3	O
otherwise	VICTRELIS.xml:S1:943:9	O
important	VICTRELIS.xml:S1:953:9	O
adverse	VICTRELIS.xml:S1:963:7	O
drug	VICTRELIS.xml:S1:971:4	O
reactions	VICTRELIS.xml:S1:976:9	O
(	VICTRELIS.xml:S1:986:1	O
ADRs	VICTRELIS.xml:S1:987:4	O
)	VICTRELIS.xml:S1:991:1	O
are	VICTRELIS.xml:S1:993:3	O
discussed	VICTRELIS.xml:S1:997:9	O
in	VICTRELIS.xml:S1:1007:2	O
detail	VICTRELIS.xml:S1:1010:6	O
in	VICTRELIS.xml:S1:1017:2	O
another	VICTRELIS.xml:S1:1020:7	O
section	VICTRELIS.xml:S1:1028:7	O
of	VICTRELIS.xml:S1:1036:2	O
the	VICTRELIS.xml:S1:1039:3	O
labeling	VICTRELIS.xml:S1:1043:8	O
:	VICTRELIS.xml:S1:1051:1	O

Anemia	VICTRELIS.xml:S1:1060:6	B-AdverseReaction
[	VICTRELIS.xml:S1:1067:1	O
see	VICTRELIS.xml:S1:1068:3	O
Warnings	VICTRELIS.xml:S1:1073:8	O
and	VICTRELIS.xml:S1:1082:3	O
Precautions	VICTRELIS.xml:S1:1086:11	O
(	VICTRELIS.xml:S1:1098:1	O
5.2	VICTRELIS.xml:S1:1099:3	O
)	VICTRELIS.xml:S1:1102:1	O
]	VICTRELIS.xml:S1:1105:1	O

Neutropenia	VICTRELIS.xml:S1:1113:11	B-AdverseReaction
[	VICTRELIS.xml:S1:1125:1	O
see	VICTRELIS.xml:S1:1126:3	O
Warnings	VICTRELIS.xml:S1:1131:8	O
and	VICTRELIS.xml:S1:1140:3	O
Precautions	VICTRELIS.xml:S1:1144:11	O
(	VICTRELIS.xml:S1:1156:1	O
5.3	VICTRELIS.xml:S1:1157:3	O
)	VICTRELIS.xml:S1:1160:1	O
]	VICTRELIS.xml:S1:1163:1	O

Pancytopenia	VICTRELIS.xml:S1:1171:12	B-AdverseReaction
[	VICTRELIS.xml:S1:1184:1	O
see	VICTRELIS.xml:S1:1185:3	O
Warnings	VICTRELIS.xml:S1:1190:8	O
and	VICTRELIS.xml:S1:1199:3	O
Precautions	VICTRELIS.xml:S1:1203:11	O
(	VICTRELIS.xml:S1:1215:1	O
5.4	VICTRELIS.xml:S1:1216:3	O
)	VICTRELIS.xml:S1:1219:1	O
]	VICTRELIS.xml:S1:1222:1	O

Hypersensitivity	VICTRELIS.xml:S1:1230:16	B-AdverseReaction
[	VICTRELIS.xml:S1:1247:1	O
see	VICTRELIS.xml:S1:1248:3	O
Contraindications	VICTRELIS.xml:S1:1253:17	O
(	VICTRELIS.xml:S1:1271:1	O
4	VICTRELIS.xml:S1:1272:1	O
)	VICTRELIS.xml:S1:1273:1	O
and	VICTRELIS.xml:S1:1276:3	O
Warnings	VICTRELIS.xml:S1:1281:8	O
and	VICTRELIS.xml:S1:1290:3	O
Precautions	VICTRELIS.xml:S1:1294:11	O
(	VICTRELIS.xml:S1:1306:1	O
5.5	VICTRELIS.xml:S1:1307:3	O
)	VICTRELIS.xml:S1:1310:1	O
]	VICTRELIS.xml:S1:1313:1	O

The	VICTRELIS.xml:S1:1321:3	O
most	VICTRELIS.xml:S1:1325:4	O
commonly	VICTRELIS.xml:S1:1330:8	O
reported	VICTRELIS.xml:S1:1339:8	O
adverse	VICTRELIS.xml:S1:1348:7	O
reactions	VICTRELIS.xml:S1:1356:9	O
(	VICTRELIS.xml:S1:1366:1	O
more	VICTRELIS.xml:S1:1367:4	O
than	VICTRELIS.xml:S1:1372:4	O
35%	VICTRELIS.xml:S1:1377:3	O
of	VICTRELIS.xml:S1:1381:2	O
subjects	VICTRELIS.xml:S1:1384:8	O
regardless	VICTRELIS.xml:S1:1393:10	O
of	VICTRELIS.xml:S1:1404:2	O
investigator	VICTRELIS.xml:S1:1407:12	O
's	VICTRELIS.xml:S1:1419:2	O
causality	VICTRELIS.xml:S1:1422:9	O
assessment	VICTRELIS.xml:S1:1432:10	O
)	VICTRELIS.xml:S1:1442:1	O
in	VICTRELIS.xml:S1:1444:2	O
adult	VICTRELIS.xml:S1:1447:5	O
subjects	VICTRELIS.xml:S1:1453:8	O
were	VICTRELIS.xml:S1:1462:4	O
fatigue	VICTRELIS.xml:S1:1467:7	B-AdverseReaction
,	VICTRELIS.xml:S1:1474:1	O
anemia	VICTRELIS.xml:S1:1476:6	B-AdverseReaction
,	VICTRELIS.xml:S1:1482:1	O
nausea	VICTRELIS.xml:S1:1484:6	B-AdverseReaction
,	VICTRELIS.xml:S1:1490:1	O
headache	VICTRELIS.xml:S1:1492:8	B-AdverseReaction
,	VICTRELIS.xml:S1:1500:1	O
and	VICTRELIS.xml:S1:1502:3	O
dysgeusia	VICTRELIS.xml:S1:1506:9	B-AdverseReaction
when	VICTRELIS.xml:S1:1516:4	O
VICTRELIS	VICTRELIS.xml:S1:1521:9	O
was	VICTRELIS.xml:S1:1531:3	O
used	VICTRELIS.xml:S1:1535:4	O
in	VICTRELIS.xml:S1:1540:2	O
combination	VICTRELIS.xml:S1:1543:11	O
with	VICTRELIS.xml:S1:1555:4	O
PegIntron	VICTRELIS.xml:S1:1560:9	O
and	VICTRELIS.xml:S1:1570:3	O
REBETOL	VICTRELIS.xml:S1:1574:7	O
.	VICTRELIS.xml:S1:1581:1	O

The	VICTRELIS.xml:S1:1587:3	O

safety	VICTRELIS.xml:S1:1591:6	O
of	VICTRELIS.xml:S1:1598:2	O
the	VICTRELIS.xml:S1:1601:3	O
combination	VICTRELIS.xml:S1:1605:11	O
of	VICTRELIS.xml:S1:1617:2	O
VICTRELIS	VICTRELIS.xml:S1:1620:9	O
800	VICTRELIS.xml:S1:1630:3	O
mg	VICTRELIS.xml:S1:1634:2	O
three	VICTRELIS.xml:S1:1637:5	O
times	VICTRELIS.xml:S1:1643:5	O
daily	VICTRELIS.xml:S1:1649:5	O
with	VICTRELIS.xml:S1:1655:4	O
PegIntron	VICTRELIS.xml:S1:1660:9	O
REBETOL	VICTRELIS.xml:S1:1670:7	O
was	VICTRELIS.xml:S1:1678:3	O
assessed	VICTRELIS.xml:S1:1682:8	O
in	VICTRELIS.xml:S1:1691:2	O
2095	VICTRELIS.xml:S1:1694:4	O
subjects	VICTRELIS.xml:S1:1699:8	O
with	VICTRELIS.xml:S1:1708:4	O
chronic	VICTRELIS.xml:S1:1713:7	O
hepatitis	VICTRELIS.xml:S1:1721:9	O
C	VICTRELIS.xml:S1:1731:1	O
in	VICTRELIS.xml:S1:1733:2	O
one	VICTRELIS.xml:S1:1736:3	O
Phase	VICTRELIS.xml:S1:1740:5	O
2	VICTRELIS.xml:S1:1746:1	O
,	VICTRELIS.xml:S1:1747:1	O
open	VICTRELIS.xml:S1:1749:4	O
-	VICTRELIS.xml:S1:1753:1	O
label	VICTRELIS.xml:S1:1754:5	O
trial	VICTRELIS.xml:S1:1760:5	O
and	VICTRELIS.xml:S1:1766:3	O
two	VICTRELIS.xml:S1:1770:3	O
Phase	VICTRELIS.xml:S1:1774:5	O
3	VICTRELIS.xml:S1:1780:1	O
,	VICTRELIS.xml:S1:1781:1	O
randomized	VICTRELIS.xml:S1:1783:10	O
,	VICTRELIS.xml:S1:1793:1	O
double	VICTRELIS.xml:S1:1795:6	O
-	VICTRELIS.xml:S1:1801:1	O
blind	VICTRELIS.xml:S1:1802:5	O
,	VICTRELIS.xml:S1:1807:1	O
placebo	VICTRELIS.xml:S1:1809:7	O
-	VICTRELIS.xml:S1:1816:1	O
controlled	VICTRELIS.xml:S1:1817:10	O
clinical	VICTRELIS.xml:S1:1828:8	O
trials	VICTRELIS.xml:S1:1837:6	O
.	VICTRELIS.xml:S1:1843:1	O

SPRINT	VICTRELIS.xml:S1:1845:6	O
-	VICTRELIS.xml:S1:1851:1	O
1	VICTRELIS.xml:S1:1852:1	O
(	VICTRELIS.xml:S1:1854:1	O
subjects	VICTRELIS.xml:S1:1855:8	O
who	VICTRELIS.xml:S1:1864:3	O
were	VICTRELIS.xml:S1:1868:4	O
previously	VICTRELIS.xml:S1:1873:10	O
untreated	VICTRELIS.xml:S1:1884:9	O
)	VICTRELIS.xml:S1:1893:1	O
evaluated	VICTRELIS.xml:S1:1895:9	O
the	VICTRELIS.xml:S1:1905:3	O
use	VICTRELIS.xml:S1:1909:3	O
of	VICTRELIS.xml:S1:1913:2	O
VICTRELIS	VICTRELIS.xml:S1:1916:9	O
in	VICTRELIS.xml:S1:1926:2	O
combination	VICTRELIS.xml:S1:1929:11	O
with	VICTRELIS.xml:S1:1941:4	O
PegIntron	VICTRELIS.xml:S1:1946:9	O
REBETOL	VICTRELIS.xml:S1:1956:7	O
with	VICTRELIS.xml:S1:1964:4	O
or	VICTRELIS.xml:S1:1969:2	O
without	VICTRELIS.xml:S1:1972:7	O
a	VICTRELIS.xml:S1:1980:1	O
four	VICTRELIS.xml:S1:1982:4	O
-	VICTRELIS.xml:S1:1986:1	O
week	VICTRELIS.xml:S1:1987:4	O
lead	VICTRELIS.xml:S1:1992:4	O
-	VICTRELIS.xml:S1:1996:1	O
in	VICTRELIS.xml:S1:1997:2	O
period	VICTRELIS.xml:S1:2000:6	O
with	VICTRELIS.xml:S1:2007:4	O
PegIntron	VICTRELIS.xml:S1:2012:9	O
REBETOL	VICTRELIS.xml:S1:2022:7	O
compared	VICTRELIS.xml:S1:2030:8	O
to	VICTRELIS.xml:S1:2039:2	O
PegIntron	VICTRELIS.xml:S1:2042:9	O
REBETOL	VICTRELIS.xml:S1:2052:7	O
alone	VICTRELIS.xml:S1:2060:5	O
.	VICTRELIS.xml:S1:2065:1	O

SPRINT	VICTRELIS.xml:S1:2067:6	O
-	VICTRELIS.xml:S1:2073:1	O
2	VICTRELIS.xml:S1:2074:1	O
(	VICTRELIS.xml:S1:2076:1	O
subjects	VICTRELIS.xml:S1:2077:8	O
who	VICTRELIS.xml:S1:2086:3	O
were	VICTRELIS.xml:S1:2090:4	O
previously	VICTRELIS.xml:S1:2095:10	O
untreated	VICTRELIS.xml:S1:2106:9	O
)	VICTRELIS.xml:S1:2115:1	O
and	VICTRELIS.xml:S1:2117:3	O
RESPOND	VICTRELIS.xml:S1:2121:7	O
-	VICTRELIS.xml:S1:2128:1	O
2	VICTRELIS.xml:S1:2129:1	O
(	VICTRELIS.xml:S1:2131:1	O
subjects	VICTRELIS.xml:S1:2132:8	O
who	VICTRELIS.xml:S1:2141:3	O
had	VICTRELIS.xml:S1:2145:3	O
failed	VICTRELIS.xml:S1:2149:6	O
previous	VICTRELIS.xml:S1:2156:8	O
therapy	VICTRELIS.xml:S1:2165:7	O
)	VICTRELIS.xml:S1:2172:1	O
evaluated	VICTRELIS.xml:S1:2174:9	O
the	VICTRELIS.xml:S1:2184:3	O
use	VICTRELIS.xml:S1:2188:3	O
of	VICTRELIS.xml:S1:2192:2	O
VICTRELIS	VICTRELIS.xml:S1:2195:9	O
800	VICTRELIS.xml:S1:2205:3	O
mg	VICTRELIS.xml:S1:2209:2	O
three	VICTRELIS.xml:S1:2212:5	O
times	VICTRELIS.xml:S1:2218:5	O
daily	VICTRELIS.xml:S1:2224:5	O
in	VICTRELIS.xml:S1:2230:2	O
combination	VICTRELIS.xml:S1:2233:11	O
with	VICTRELIS.xml:S1:2245:4	O
PegIntron	VICTRELIS.xml:S1:2250:9	O
REBETOL	VICTRELIS.xml:S1:2260:7	O
with	VICTRELIS.xml:S1:2268:4	O
a	VICTRELIS.xml:S1:2273:1	O
four	VICTRELIS.xml:S1:2275:4	O
-	VICTRELIS.xml:S1:2279:1	O
week	VICTRELIS.xml:S1:2280:4	O
lead	VICTRELIS.xml:S1:2285:4	O
-	VICTRELIS.xml:S1:2289:1	O
in	VICTRELIS.xml:S1:2290:2	O
period	VICTRELIS.xml:S1:2293:6	O
with	VICTRELIS.xml:S1:2300:4	O
PegIntron	VICTRELIS.xml:S1:2305:9	O
REBETOL	VICTRELIS.xml:S1:2315:7	O
compared	VICTRELIS.xml:S1:2323:8	O
to	VICTRELIS.xml:S1:2332:2	O
PegIntron	VICTRELIS.xml:S1:2335:9	O
REBETOL	VICTRELIS.xml:S1:2345:7	O
alone	VICTRELIS.xml:S1:2353:5	O
[	VICTRELIS.xml:S1:2360:1	O
see	VICTRELIS.xml:S1:2361:3	O
Clinical	VICTRELIS.xml:S1:2366:8	O
Studies	VICTRELIS.xml:S1:2375:7	O
(	VICTRELIS.xml:S1:2383:1	O
14	VICTRELIS.xml:S1:2384:2	O
)	VICTRELIS.xml:S1:2386:1	O
]	VICTRELIS.xml:S1:2389:1	O
.	VICTRELIS.xml:S1:2392:1	O

The	VICTRELIS.xml:S1:2394:3	O
population	VICTRELIS.xml:S1:2398:10	O
studied	VICTRELIS.xml:S1:2409:7	O
had	VICTRELIS.xml:S1:2417:3	O
a	VICTRELIS.xml:S1:2421:1	O
mean	VICTRELIS.xml:S1:2423:4	O
age	VICTRELIS.xml:S1:2428:3	O
of	VICTRELIS.xml:S1:2432:2	O
49	VICTRELIS.xml:S1:2435:2	O
years	VICTRELIS.xml:S1:2438:5	O
(	VICTRELIS.xml:S1:2444:1	O
3%	VICTRELIS.xml:S1:2445:2	O
of	VICTRELIS.xml:S1:2448:2	O
subjects	VICTRELIS.xml:S1:2451:8	O
were	VICTRELIS.xml:S1:2460:4	O
older	VICTRELIS.xml:S1:2465:5	O
than	VICTRELIS.xml:S1:2471:4	O
65	VICTRELIS.xml:S1:2476:2	O
years	VICTRELIS.xml:S1:2479:5	O
of	VICTRELIS.xml:S1:2485:2	O
age	VICTRELIS.xml:S1:2488:3	O
)	VICTRELIS.xml:S1:2491:1	O
,	VICTRELIS.xml:S1:2492:1	O
39%	VICTRELIS.xml:S1:2494:3	O
were	VICTRELIS.xml:S1:2498:4	O
female	VICTRELIS.xml:S1:2503:6	O
,	VICTRELIS.xml:S1:2509:1	O
82%	VICTRELIS.xml:S1:2511:3	O
were	VICTRELIS.xml:S1:2515:4	O
white	VICTRELIS.xml:S1:2520:5	O
and	VICTRELIS.xml:S1:2526:3	O
15%	VICTRELIS.xml:S1:2530:3	O
were	VICTRELIS.xml:S1:2534:4	O
black	VICTRELIS.xml:S1:2539:5	O
.	VICTRELIS.xml:S1:2544:1	O

During	VICTRELIS.xml:S1:2550:6	O
the	VICTRELIS.xml:S1:2557:3	O
four	VICTRELIS.xml:S1:2561:4	O
week	VICTRELIS.xml:S1:2566:4	O
lead	VICTRELIS.xml:S1:2571:4	O
-	VICTRELIS.xml:S1:2575:1	O
in	VICTRELIS.xml:S1:2576:2	O
period	VICTRELIS.xml:S1:2579:6	O
with	VICTRELIS.xml:S1:2586:4	O
PegIntron	VICTRELIS.xml:S1:2591:9	O
REBETOL	VICTRELIS.xml:S1:2601:7	O
in	VICTRELIS.xml:S1:2609:2	O
subjects	VICTRELIS.xml:S1:2612:8	O
treated	VICTRELIS.xml:S1:2621:7	O
with	VICTRELIS.xml:S1:2629:4	O
the	VICTRELIS.xml:S1:2634:3	O
combination	VICTRELIS.xml:S1:2638:11	O
of	VICTRELIS.xml:S1:2650:2	O
VICTRELIS	VICTRELIS.xml:S1:2653:9	O
with	VICTRELIS.xml:S1:2663:4	O
PegIntron	VICTRELIS.xml:S1:2668:9	O
REBETOL	VICTRELIS.xml:S1:2678:7	O
,	VICTRELIS.xml:S1:2685:1	O
28	VICTRELIS.xml:S1:2687:2	O
1263	VICTRELIS.xml:S1:2690:4	O
(	VICTRELIS.xml:S1:2695:1	O
2%	VICTRELIS.xml:S1:2696:2	O
)	VICTRELIS.xml:S1:2698:1	O
subjects	VICTRELIS.xml:S1:2700:8	O
experienced	VICTRELIS.xml:S1:2709:11	O
adverse	VICTRELIS.xml:S1:2721:7	O
reactions	VICTRELIS.xml:S1:2729:9	O
leading	VICTRELIS.xml:S1:2739:7	O
to	VICTRELIS.xml:S1:2747:2	O
discontinuation	VICTRELIS.xml:S1:2750:15	O
of	VICTRELIS.xml:S1:2766:2	O
treatment	VICTRELIS.xml:S1:2769:9	O
.	VICTRELIS.xml:S1:2778:1	O

During	VICTRELIS.xml:S1:2780:6	O
the	VICTRELIS.xml:S1:2787:3	O
entire	VICTRELIS.xml:S1:2791:6	O
course	VICTRELIS.xml:S1:2798:6	O
of	VICTRELIS.xml:S1:2805:2	O
treatment	VICTRELIS.xml:S1:2808:9	O
,	VICTRELIS.xml:S1:2817:1	O
the	VICTRELIS.xml:S1:2819:3	O
proportion	VICTRELIS.xml:S1:2823:10	O
of	VICTRELIS.xml:S1:2834:2	O
subjects	VICTRELIS.xml:S1:2837:8	O
who	VICTRELIS.xml:S1:2846:3	O
discontinued	VICTRELIS.xml:S1:2850:12	O
treatment	VICTRELIS.xml:S1:2863:9	O
due	VICTRELIS.xml:S1:2873:3	O
to	VICTRELIS.xml:S1:2877:2	O
adverse	VICTRELIS.xml:S1:2880:7	O
reactions	VICTRELIS.xml:S1:2888:9	O
was	VICTRELIS.xml:S1:2898:3	O
13%	VICTRELIS.xml:S1:2902:3	O
for	VICTRELIS.xml:S1:2906:3	O
subjects	VICTRELIS.xml:S1:2910:8	O
receiving	VICTRELIS.xml:S1:2919:9	O
the	VICTRELIS.xml:S1:2929:3	O
combination	VICTRELIS.xml:S1:2933:11	O
of	VICTRELIS.xml:S1:2945:2	O
VICTRELIS	VICTRELIS.xml:S1:2948:9	O
with	VICTRELIS.xml:S1:2958:4	O
PegIntron	VICTRELIS.xml:S1:2963:9	O
REBETOL	VICTRELIS.xml:S1:2973:7	O
and	VICTRELIS.xml:S1:2981:3	O
12%	VICTRELIS.xml:S1:2985:3	O
for	VICTRELIS.xml:S1:2989:3	O
subjects	VICTRELIS.xml:S1:2993:8	O
receiving	VICTRELIS.xml:S1:3002:9	O
PegIntron	VICTRELIS.xml:S1:3012:9	O
REBETOL	VICTRELIS.xml:S1:3022:7	O
alone	VICTRELIS.xml:S1:3030:5	O
.	VICTRELIS.xml:S1:3035:1	O

Events	VICTRELIS.xml:S1:3037:6	O
resulting	VICTRELIS.xml:S1:3044:9	O
in	VICTRELIS.xml:S1:3054:2	O
discontinuation	VICTRELIS.xml:S1:3057:15	O
were	VICTRELIS.xml:S1:3073:4	O
similar	VICTRELIS.xml:S1:3078:7	O
to	VICTRELIS.xml:S1:3086:2	O
those	VICTRELIS.xml:S1:3089:5	O
seen	VICTRELIS.xml:S1:3095:4	O
in	VICTRELIS.xml:S1:3100:2	O
previous	VICTRELIS.xml:S1:3103:8	O
studies	VICTRELIS.xml:S1:3112:7	O
with	VICTRELIS.xml:S1:3120:4	O
PegIntron	VICTRELIS.xml:S1:3125:9	O
REBETOL	VICTRELIS.xml:S1:3135:7	O
.	VICTRELIS.xml:S1:3142:1	O

Only	VICTRELIS.xml:S1:3144:4	O
anemia	VICTRELIS.xml:S1:3149:6	B-AdverseReaction
and	VICTRELIS.xml:S1:3156:3	O
fatigue	VICTRELIS.xml:S1:3160:7	B-AdverseReaction
were	VICTRELIS.xml:S1:3168:4	O
reported	VICTRELIS.xml:S1:3173:8	O
as	VICTRELIS.xml:S1:3182:2	O
events	VICTRELIS.xml:S1:3185:6	O
that	VICTRELIS.xml:S1:3192:4	O
led	VICTRELIS.xml:S1:3197:3	O
to	VICTRELIS.xml:S1:3201:2	O
discontinuation	VICTRELIS.xml:S1:3204:15	O
in	VICTRELIS.xml:S1:3220:2	O
more	VICTRELIS.xml:S1:3223:4	O
than	VICTRELIS.xml:S1:3228:4	O
1%	VICTRELIS.xml:S1:3233:2	O
of	VICTRELIS.xml:S1:3236:2	O
subjects	VICTRELIS.xml:S1:3239:8	O
in	VICTRELIS.xml:S1:3248:2	O
any	VICTRELIS.xml:S1:3251:3	O
arm	VICTRELIS.xml:S1:3255:3	O
.	VICTRELIS.xml:S1:3258:1	O

Adverse	VICTRELIS.xml:S1:3264:7	O
reactions	VICTRELIS.xml:S1:3272:9	O
that	VICTRELIS.xml:S1:3282:4	O
led	VICTRELIS.xml:S1:3287:3	O
to	VICTRELIS.xml:S1:3291:2	O
dose	VICTRELIS.xml:S1:3294:4	O
modifications	VICTRELIS.xml:S1:3299:13	O
of	VICTRELIS.xml:S1:3313:2	O
any	VICTRELIS.xml:S1:3316:3	O
drug	VICTRELIS.xml:S1:3320:4	O
(	VICTRELIS.xml:S1:3325:1	O
primarily	VICTRELIS.xml:S1:3326:9	O
PegIntron	VICTRELIS.xml:S1:3336:9	O
and	VICTRELIS.xml:S1:3346:3	O
REBETOL	VICTRELIS.xml:S1:3350:7	O
)	VICTRELIS.xml:S1:3357:1	O
occurred	VICTRELIS.xml:S1:3359:8	O
in	VICTRELIS.xml:S1:3368:2	O
39%	VICTRELIS.xml:S1:3371:3	O
of	VICTRELIS.xml:S1:3375:2	O
subjects	VICTRELIS.xml:S1:3378:8	O
receiving	VICTRELIS.xml:S1:3387:9	O
the	VICTRELIS.xml:S1:3397:3	O
combination	VICTRELIS.xml:S1:3401:11	O
of	VICTRELIS.xml:S1:3413:2	O
VICTRELIS	VICTRELIS.xml:S1:3416:9	O
with	VICTRELIS.xml:S1:3426:4	O
PegIntron	VICTRELIS.xml:S1:3431:9	O
REBETOL	VICTRELIS.xml:S1:3441:7	O
compared	VICTRELIS.xml:S1:3449:8	O
to	VICTRELIS.xml:S1:3458:2	O
24%	VICTRELIS.xml:S1:3461:3	O
of	VICTRELIS.xml:S1:3465:2	O
subjects	VICTRELIS.xml:S1:3468:8	O
receiving	VICTRELIS.xml:S1:3477:9	O
PegIntron	VICTRELIS.xml:S1:3487:9	O
REBETOL	VICTRELIS.xml:S1:3497:7	O
alone	VICTRELIS.xml:S1:3505:5	O
.	VICTRELIS.xml:S1:3510:1	O

The	VICTRELIS.xml:S1:3512:3	O
most	VICTRELIS.xml:S1:3516:4	O
common	VICTRELIS.xml:S1:3521:6	O
reason	VICTRELIS.xml:S1:3528:6	O
for	VICTRELIS.xml:S1:3535:3	O
dose	VICTRELIS.xml:S1:3539:4	O
reduction	VICTRELIS.xml:S1:3544:9	O
was	VICTRELIS.xml:S1:3554:3	O
anemia	VICTRELIS.xml:S1:3558:6	B-AdverseReaction
,	VICTRELIS.xml:S1:3564:1	O
which	VICTRELIS.xml:S1:3566:5	O
occurred	VICTRELIS.xml:S1:3572:8	O
more	VICTRELIS.xml:S1:3581:4	O
frequently	VICTRELIS.xml:S1:3586:10	O
in	VICTRELIS.xml:S1:3597:2	O
subjects	VICTRELIS.xml:S1:3600:8	O
receiving	VICTRELIS.xml:S1:3609:9	O
the	VICTRELIS.xml:S1:3619:3	O
combination	VICTRELIS.xml:S1:3623:11	O
of	VICTRELIS.xml:S1:3635:2	O
VICTRELIS	VICTRELIS.xml:S1:3638:9	O
with	VICTRELIS.xml:S1:3648:4	O
PegIntron	VICTRELIS.xml:S1:3653:9	O
REBETOL	VICTRELIS.xml:S1:3663:7	O
than	VICTRELIS.xml:S1:3671:4	O
in	VICTRELIS.xml:S1:3676:2	O
subjects	VICTRELIS.xml:S1:3679:8	O
receiving	VICTRELIS.xml:S1:3688:9	O
PegIntron	VICTRELIS.xml:S1:3698:9	O
REBETOL	VICTRELIS.xml:S1:3708:7	O
alone	VICTRELIS.xml:S1:3716:5	O
.	VICTRELIS.xml:S1:3721:1	O

Serious	VICTRELIS.xml:S1:3727:7	O
adverse	VICTRELIS.xml:S1:3735:7	O
events	VICTRELIS.xml:S1:3743:6	O
were	VICTRELIS.xml:S1:3750:4	O
reported	VICTRELIS.xml:S1:3755:8	O
in	VICTRELIS.xml:S1:3764:2	O
11%	VICTRELIS.xml:S1:3767:3	O
of	VICTRELIS.xml:S1:3771:2	O
subjects	VICTRELIS.xml:S1:3774:8	O
receiving	VICTRELIS.xml:S1:3783:9	O
the	VICTRELIS.xml:S1:3793:3	O
combination	VICTRELIS.xml:S1:3797:11	O
of	VICTRELIS.xml:S1:3809:2	O
VICTRELIS	VICTRELIS.xml:S1:3812:9	O
with	VICTRELIS.xml:S1:3822:4	O
PegIntron	VICTRELIS.xml:S1:3827:9	O
REBETOL	VICTRELIS.xml:S1:3837:7	O
and	VICTRELIS.xml:S1:3845:3	O
in	VICTRELIS.xml:S1:3849:2	O
8%	VICTRELIS.xml:S1:3852:2	O
of	VICTRELIS.xml:S1:3855:2	O
subjects	VICTRELIS.xml:S1:3858:8	O
receiving	VICTRELIS.xml:S1:3867:9	O
PegIntron	VICTRELIS.xml:S1:3877:9	O
REBETOL	VICTRELIS.xml:S1:3887:7	O
.	VICTRELIS.xml:S1:3894:1	O

Adverse	VICTRELIS.xml:S1:3900:7	O
events	VICTRELIS.xml:S1:3908:6	O
(	VICTRELIS.xml:S1:3915:1	O
regardless	VICTRELIS.xml:S1:3916:10	O
of	VICTRELIS.xml:S1:3927:2	O
investigator	VICTRELIS.xml:S1:3930:12	O
's	VICTRELIS.xml:S1:3942:2	O
causality	VICTRELIS.xml:S1:3945:9	O
assessment	VICTRELIS.xml:S1:3955:10	O
)	VICTRELIS.xml:S1:3965:1	O
reported	VICTRELIS.xml:S1:3967:8	O
in	VICTRELIS.xml:S1:3976:2	O
greater	VICTRELIS.xml:S1:3979:7	O
than	VICTRELIS.xml:S1:3987:4	O
or	VICTRELIS.xml:S1:3992:2	O
equal	VICTRELIS.xml:S1:3995:5	O
to	VICTRELIS.xml:S1:4001:2	O
10%	VICTRELIS.xml:S1:4004:3	O
of	VICTRELIS.xml:S1:4008:2	O
subjects	VICTRELIS.xml:S1:4011:8	O
receiving	VICTRELIS.xml:S1:4020:9	O
the	VICTRELIS.xml:S1:4030:3	O
combination	VICTRELIS.xml:S1:4034:11	O
of	VICTRELIS.xml:S1:4046:2	O
VICTRELIS	VICTRELIS.xml:S1:4049:9	O
with	VICTRELIS.xml:S1:4059:4	O
PegIntron	VICTRELIS.xml:S1:4064:9	O
REBETOL	VICTRELIS.xml:S1:4074:7	O
and	VICTRELIS.xml:S1:4082:3	O
reported	VICTRELIS.xml:S1:4086:8	O
at	VICTRELIS.xml:S1:4095:2	O
a	VICTRELIS.xml:S1:4098:1	O
rate	VICTRELIS.xml:S1:4100:4	O
of	VICTRELIS.xml:S1:4105:2	O
greater	VICTRELIS.xml:S1:4108:7	O
than	VICTRELIS.xml:S1:4116:4	O
or	VICTRELIS.xml:S1:4121:2	O
equal	VICTRELIS.xml:S1:4124:5	O
to	VICTRELIS.xml:S1:4130:2	O
5%	VICTRELIS.xml:S1:4133:2	O
than	VICTRELIS.xml:S1:4136:4	O
PegIntron	VICTRELIS.xml:S1:4141:9	O
REBETOL	VICTRELIS.xml:S1:4151:7	O
alone	VICTRELIS.xml:S1:4159:5	O
in	VICTRELIS.xml:S1:4165:2	O
SPRINT	VICTRELIS.xml:S1:4168:6	O
-	VICTRELIS.xml:S1:4174:1	O
1	VICTRELIS.xml:S1:4175:1	O
,	VICTRELIS.xml:S1:4176:1	O
SPRINT	VICTRELIS.xml:S1:4178:6	O
-	VICTRELIS.xml:S1:4184:1	O
2	VICTRELIS.xml:S1:4185:1	O
,	VICTRELIS.xml:S1:4186:1	O
and	VICTRELIS.xml:S1:4188:3	O
RESPOND	VICTRELIS.xml:S1:4192:7	O
-	VICTRELIS.xml:S1:4199:1	O
2	VICTRELIS.xml:S1:4200:1	O
are	VICTRELIS.xml:S1:4202:3	O
presented	VICTRELIS.xml:S1:4206:9	O
in	VICTRELIS.xml:S1:4216:2	O
Table	VICTRELIS.xml:S1:4220:5	O
3	VICTRELIS.xml:S1:4226:1	O
.	VICTRELIS.xml:S1:4229:1	O

Table	VICTRELIS.xml:S1:4235:5	O
3	VICTRELIS.xml:S1:4241:1	O
Adverse	VICTRELIS.xml:S1:4243:7	O
Events	VICTRELIS.xml:S1:4251:6	O
Reported	VICTRELIS.xml:S1:4258:8	O
in	VICTRELIS.xml:S1:4267:2	O
10%	VICTRELIS.xml:S1:4272:3	O
of	VICTRELIS.xml:S1:4276:2	O
Subjects	VICTRELIS.xml:S1:4279:8	O
Receiving	VICTRELIS.xml:S1:4288:9	O
the	VICTRELIS.xml:S1:4298:3	O
Combination	VICTRELIS.xml:S1:4302:11	O
of	VICTRELIS.xml:S1:4314:2	O
VICTRELIS	VICTRELIS.xml:S1:4317:9	O
with	VICTRELIS.xml:S1:4327:4	O
PegIntron	VICTRELIS.xml:S1:4332:9	O
REBETOL	VICTRELIS.xml:S1:4342:7	O
and	VICTRELIS.xml:S1:4350:3	O
Reported	VICTRELIS.xml:S1:4354:8	O
at	VICTRELIS.xml:S1:4363:2	O
a	VICTRELIS.xml:S1:4366:1	O
Rate	VICTRELIS.xml:S1:4368:4	O
of	VICTRELIS.xml:S1:4373:2	O
5%	VICTRELIS.xml:S1:4378:2	O
than	VICTRELIS.xml:S1:4381:4	O
PegIntron	VICTRELIS.xml:S1:4386:9	O
REBETOL	VICTRELIS.xml:S1:4396:7	O
alone	VICTRELIS.xml:S1:4404:5	O

Adverse	VICTRELIS.xml:S1:4412:7	O
Events	VICTRELIS.xml:S1:4420:6	O
Previously	VICTRELIS.xml:S1:4438:10	O
Untreated	VICTRELIS.xml:S1:4449:9	O
(	VICTRELIS.xml:S1:4458:1	O
SPRINT	VICTRELIS.xml:S1:4459:6	O
-	VICTRELIS.xml:S1:4465:1	O
1	VICTRELIS.xml:S1:4466:1	O
and	VICTRELIS.xml:S1:4468:3	O
SPRINT	VICTRELIS.xml:S1:4472:6	O
-	VICTRELIS.xml:S1:4478:1	O
2	VICTRELIS.xml:S1:4479:1	O
)	VICTRELIS.xml:S1:4480:1	O
Previous	VICTRELIS.xml:S1:4483:8	O
Treatment	VICTRELIS.xml:S1:4492:9	O
Failures	VICTRELIS.xml:S1:4502:8	O
(	VICTRELIS.xml:S1:4510:1	O
RESPOND	VICTRELIS.xml:S1:4511:7	O
-	VICTRELIS.xml:S1:4518:1	O
2	VICTRELIS.xml:S1:4519:1	O
)	VICTRELIS.xml:S1:4520:1	O

Percentage	VICTRELIS.xml:S1:4552:10	O
of	VICTRELIS.xml:S1:4563:2	O
Subjects	VICTRELIS.xml:S1:4566:8	O
Reporting	VICTRELIS.xml:S1:4575:9	O
Adverse	VICTRELIS.xml:S1:4585:7	O
Events	VICTRELIS.xml:S1:4593:6	O
Percentage	VICTRELIS.xml:S1:4601:10	O
of	VICTRELIS.xml:S1:4612:2	O
Subjects	VICTRELIS.xml:S1:4615:8	O
Reporting	VICTRELIS.xml:S1:4624:9	O
Adverse	VICTRELIS.xml:S1:4634:7	O
Events	VICTRELIS.xml:S1:4642:6	O

Body	VICTRELIS.xml:S1:4653:4	O
System	VICTRELIS.xml:S1:4658:6	O
Organ	VICTRELIS.xml:S1:4665:5	O
Class	VICTRELIS.xml:S1:4671:5	O
VICTRELIS	VICTRELIS.xml:S1:4679:9	O
PegIntron	VICTRELIS.xml:S1:4691:9	O
REBETOL	VICTRELIS.xml:S1:4703:7	O
(	VICTRELIS.xml:S1:4710:1	O
n	VICTRELIS.xml:S1:4711:1	O
1225	VICTRELIS.xml:S1:4713:4	O
)	VICTRELIS.xml:S1:4717:1	O
PegIntron	VICTRELIS.xml:S1:4720:9	O
REBETOL	VICTRELIS.xml:S1:4732:7	O
(	VICTRELIS.xml:S1:4739:1	O
n	VICTRELIS.xml:S1:4740:1	O
467	VICTRELIS.xml:S1:4742:3	O
)	VICTRELIS.xml:S1:4745:1	O
VICTRELIS	VICTRELIS.xml:S1:4748:9	O
PegIntron	VICTRELIS.xml:S1:4760:9	O
REBETOL	VICTRELIS.xml:S1:4772:7	O
(	VICTRELIS.xml:S1:4779:1	O
n	VICTRELIS.xml:S1:4780:1	O
323	VICTRELIS.xml:S1:4782:3	O
)	VICTRELIS.xml:S1:4785:1	O
PegIntron	VICTRELIS.xml:S1:4788:9	O
REBETOL	VICTRELIS.xml:S1:4800:7	O
(	VICTRELIS.xml:S1:4807:1	O
n	VICTRELIS.xml:S1:4808:1	O
80	VICTRELIS.xml:S1:4810:2	O
)	VICTRELIS.xml:S1:4812:1	O

Median	VICTRELIS.xml:S1:4823:6	O

Exposure	VICTRELIS.xml:S1:4830:8	O
(	VICTRELIS.xml:S1:4839:1	O
days	VICTRELIS.xml:S1:4840:4	O
)	VICTRELIS.xml:S1:4844:1	O
197	VICTRELIS.xml:S1:4857:3	O
216	VICTRELIS.xml:S1:4878:3	O
253	VICTRELIS.xml:S1:4899:3	O
104	VICTRELIS.xml:S1:4920:3	O

Blood	VICTRELIS.xml:S1:4938:5	O
and	VICTRELIS.xml:S1:4944:3	O
Lymphatic	VICTRELIS.xml:S1:4948:9	O
System	VICTRELIS.xml:S1:4958:6	O
Disorders	VICTRELIS.xml:S1:4965:9	O

Anemia	VICTRELIS.xml:S1:4981:6	B-AdverseReaction
50	VICTRELIS.xml:S1:5015:2	O
30	VICTRELIS.xml:S1:5036:2	O
45	VICTRELIS.xml:S1:5057:2	O
20	VICTRELIS.xml:S1:5078:2	O

Neutropenia	VICTRELIS.xml:S1:5094:11	B-AdverseReaction
25	VICTRELIS.xml:S1:5128:2	O
19	VICTRELIS.xml:S1:5149:2	O
14	VICTRELIS.xml:S1:5170:2	O
10	VICTRELIS.xml:S1:5191:2	O

Gastrointestinal	VICTRELIS.xml:S1:5209:16	O
Disorders	VICTRELIS.xml:S1:5226:9	O

Nausea	VICTRELIS.xml:S1:5242:6	B-AdverseReaction
46	VICTRELIS.xml:S1:5276:2	O
42	VICTRELIS.xml:S1:5297:2	O
43	VICTRELIS.xml:S1:5318:2	O
38	VICTRELIS.xml:S1:5339:2	O

Dysgeusia	VICTRELIS.xml:S1:5355:9	B-AdverseReaction
35	VICTRELIS.xml:S1:5389:2	O
16	VICTRELIS.xml:S1:5410:2	O
44	VICTRELIS.xml:S1:5431:2	O
11	VICTRELIS.xml:S1:5452:2	O

Diarrhea	VICTRELIS.xml:S1:5468:8	B-AdverseReaction
25	VICTRELIS.xml:S1:5502:2	O
22	VICTRELIS.xml:S1:5523:2	O
24	VICTRELIS.xml:S1:5544:2	O
16	VICTRELIS.xml:S1:5565:2	O

Vomiting	VICTRELIS.xml:S1:5581:8	B-AdverseReaction
20	VICTRELIS.xml:S1:5615:2	O
13	VICTRELIS.xml:S1:5636:2	O
15	VICTRELIS.xml:S1:5657:2	O
8	VICTRELIS.xml:S1:5679:1	O

Dry	VICTRELIS.xml:S1:5694:3	B-AdverseReaction
Mouth	VICTRELIS.xml:S1:5698:5	I-AdverseReaction
11	VICTRELIS.xml:S1:5728:2	O
10	VICTRELIS.xml:S1:5749:2	O
15	VICTRELIS.xml:S1:5770:2	O
9	VICTRELIS.xml:S1:5792:1	O

General	VICTRELIS.xml:S1:5809:7	O
Disorders	VICTRELIS.xml:S1:5817:9	O
and	VICTRELIS.xml:S1:5827:3	O
Administration	VICTRELIS.xml:S1:5831:14	O
Site	VICTRELIS.xml:S1:5846:4	O
Conditions	VICTRELIS.xml:S1:5851:10	O

Fatigue	VICTRELIS.xml:S1:5868:7	B-AdverseReaction
58	VICTRELIS.xml:S1:5902:2	O
59	VICTRELIS.xml:S1:5923:2	O
55	VICTRELIS.xml:S1:5944:2	O
50	VICTRELIS.xml:S1:5965:2	O

Chills	VICTRELIS.xml:S1:5981:6	B-AdverseReaction
34	VICTRELIS.xml:S1:6015:2	O
29	VICTRELIS.xml:S1:6036:2	O
33	VICTRELIS.xml:S1:6057:2	O
30	VICTRELIS.xml:S1:6078:2	O

Asthenia	VICTRELIS.xml:S1:6094:8	B-AdverseReaction
15	VICTRELIS.xml:S1:6128:2	O
18	VICTRELIS.xml:S1:6149:2	O
21	VICTRELIS.xml:S1:6170:2	O
16	VICTRELIS.xml:S1:6191:2	O

Metabolism	VICTRELIS.xml:S1:6209:10	O
and	VICTRELIS.xml:S1:6220:3	O
Nutrition	VICTRELIS.xml:S1:6224:9	O
Disorders	VICTRELIS.xml:S1:6234:9	O

Decreased	VICTRELIS.xml:S1:6250:9	B-AdverseReaction
Appetite	VICTRELIS.xml:S1:6260:8	I-AdverseReaction
25	VICTRELIS.xml:S1:6284:2	O
24	VICTRELIS.xml:S1:6305:2	O
26	VICTRELIS.xml:S1:6326:2	O
16	VICTRELIS.xml:S1:6347:2	O

Musculoskeletal	VICTRELIS.xml:S1:6365:15	O
and	VICTRELIS.xml:S1:6381:3	O
Connective	VICTRELIS.xml:S1:6385:10	O
Tissue	VICTRELIS.xml:S1:6396:6	O
Disorders	VICTRELIS.xml:S1:6403:9	O

Arthralgia	VICTRELIS.xml:S1:6419:10	B-AdverseReaction
19	VICTRELIS.xml:S1:6453:2	O
19	VICTRELIS.xml:S1:6474:2	O
23	VICTRELIS.xml:S1:6495:2	O
16	VICTRELIS.xml:S1:6516:2	O

Nervous	VICTRELIS.xml:S1:6534:7	O
System	VICTRELIS.xml:S1:6542:6	O
Disorders	VICTRELIS.xml:S1:6549:9	O

Dizziness	VICTRELIS.xml:S1:6565:9	B-AdverseReaction
19	VICTRELIS.xml:S1:6599:2	O
16	VICTRELIS.xml:S1:6620:2	O
16	VICTRELIS.xml:S1:6641:2	O
10	VICTRELIS.xml:S1:6662:2	O

Psychiatric	VICTRELIS.xml:S1:6680:11	O
Disorders	VICTRELIS.xml:S1:6692:9	O

Insomnia	VICTRELIS.xml:S1:6708:8	B-AdverseReaction
34	VICTRELIS.xml:S1:6742:2	O
34	VICTRELIS.xml:S1:6763:2	O
30	VICTRELIS.xml:S1:6784:2	O
24	VICTRELIS.xml:S1:6805:2	O

Irritability	VICTRELIS.xml:S1:6821:12	B-AdverseReaction
22	VICTRELIS.xml:S1:6855:2	O
23	VICTRELIS.xml:S1:6876:2	O
21	VICTRELIS.xml:S1:6897:2	O
13	VICTRELIS.xml:S1:6918:2	O

Respiratory	VICTRELIS.xml:S1:6936:11	O
,	VICTRELIS.xml:S1:6947:1	O
Thoracic	VICTRELIS.xml:S1:6949:8	O
,	VICTRELIS.xml:S1:6957:1	O
and	VICTRELIS.xml:S1:6959:3	O
Mediastinal	VICTRELIS.xml:S1:6963:11	O
Disorders	VICTRELIS.xml:S1:6975:9	O

Dyspnea	VICTRELIS.xml:S1:6991:7	B-AdverseReaction
Exertional	VICTRELIS.xml:S1:6999:10	I-AdverseReaction
8	VICTRELIS.xml:S1:7026:1	O
8	VICTRELIS.xml:S1:7047:1	O
11	VICTRELIS.xml:S1:7067:2	O
5	VICTRELIS.xml:S1:7089:1	O

Skin	VICTRELIS.xml:S1:7106:4	O
and	VICTRELIS.xml:S1:7111:3	O
Subcutaneous	VICTRELIS.xml:S1:7115:12	O
Tissue	VICTRELIS.xml:S1:7128:6	O
Disorders	VICTRELIS.xml:S1:7135:9	O

Alopecia	VICTRELIS.xml:S1:7151:8	B-AdverseReaction
27	VICTRELIS.xml:S1:7185:2	O
27	VICTRELIS.xml:S1:7206:2	O
22	VICTRELIS.xml:S1:7227:2	O
16	VICTRELIS.xml:S1:7248:2	O

Dry	VICTRELIS.xml:S1:7264:3	B-AdverseReaction
Skin	VICTRELIS.xml:S1:7268:4	I-AdverseReaction
18	VICTRELIS.xml:S1:7298:2	O
18	VICTRELIS.xml:S1:7319:2	O
22	VICTRELIS.xml:S1:7340:2	O
9	VICTRELIS.xml:S1:7362:1	O

Rash	VICTRELIS.xml:S1:7377:4	B-AdverseReaction
17	VICTRELIS.xml:S1:7411:2	O
19	VICTRELIS.xml:S1:7432:2	O
16	VICTRELIS.xml:S1:7453:2	O
6	VICTRELIS.xml:S1:7475:1	O

Other	VICTRELIS.xml:S1:7504:5	O
Important	VICTRELIS.xml:S1:7510:9	O
Adverse	VICTRELIS.xml:S1:7520:7	O
Reactions	VICTRELIS.xml:S1:7528:9	O
Reported	VICTRELIS.xml:S1:7538:8	O
in	VICTRELIS.xml:S1:7547:2	O
Clinical	VICTRELIS.xml:S1:7550:8	O
Trials	VICTRELIS.xml:S1:7559:6	O

Among	VICTRELIS.xml:S1:7572:5	O

subjects	VICTRELIS.xml:S1:7578:8	O
(	VICTRELIS.xml:S1:7587:1	O
previously	VICTRELIS.xml:S1:7588:10	O
untreated	VICTRELIS.xml:S1:7599:9	O
subjects	VICTRELIS.xml:S1:7609:8	O
or	VICTRELIS.xml:S1:7618:2	O
those	VICTRELIS.xml:S1:7621:5	O
who	VICTRELIS.xml:S1:7627:3	O
failed	VICTRELIS.xml:S1:7631:6	O
previous	VICTRELIS.xml:S1:7638:8	O
therapy	VICTRELIS.xml:S1:7647:7	O
)	VICTRELIS.xml:S1:7654:1	O
who	VICTRELIS.xml:S1:7656:3	O
received	VICTRELIS.xml:S1:7660:8	O
VICTRELIS	VICTRELIS.xml:S1:7669:9	O
in	VICTRELIS.xml:S1:7679:2	O
combination	VICTRELIS.xml:S1:7682:11	O
with	VICTRELIS.xml:S1:7694:4	O
peginterferon	VICTRELIS.xml:S1:7699:13	O
alfa	VICTRELIS.xml:S1:7713:4	O
and	VICTRELIS.xml:S1:7718:3	O
ribavirin	VICTRELIS.xml:S1:7722:9	O
,	VICTRELIS.xml:S1:7731:1	O
the	VICTRELIS.xml:S1:7733:3	O
following	VICTRELIS.xml:S1:7737:9	O
adverse	VICTRELIS.xml:S1:7747:7	O
drug	VICTRELIS.xml:S1:7755:4	O
reactions	VICTRELIS.xml:S1:7760:9	O
were	VICTRELIS.xml:S1:7770:4	O
reported	VICTRELIS.xml:S1:7775:8	O
.	VICTRELIS.xml:S1:7783:1	O

These	VICTRELIS.xml:S1:7785:5	O
events	VICTRELIS.xml:S1:7791:6	O
are	VICTRELIS.xml:S1:7798:3	O
notable	VICTRELIS.xml:S1:7802:7	O
because	VICTRELIS.xml:S1:7810:7	O
of	VICTRELIS.xml:S1:7818:2	O
their	VICTRELIS.xml:S1:7821:5	O
seriousness	VICTRELIS.xml:S1:7827:11	O
,	VICTRELIS.xml:S1:7838:1	O
severity	VICTRELIS.xml:S1:7840:8	O
,	VICTRELIS.xml:S1:7848:1	O
or	VICTRELIS.xml:S1:7850:2	O
increased	VICTRELIS.xml:S1:7853:9	O
frequency	VICTRELIS.xml:S1:7863:9	O
in	VICTRELIS.xml:S1:7873:2	O
subjects	VICTRELIS.xml:S1:7876:8	O
who	VICTRELIS.xml:S1:7885:3	O
received	VICTRELIS.xml:S1:7889:8	O
VICTRELIS	VICTRELIS.xml:S1:7898:9	O
in	VICTRELIS.xml:S1:7908:2	O
combination	VICTRELIS.xml:S1:7911:11	O
with	VICTRELIS.xml:S1:7923:4	O
peginterferon	VICTRELIS.xml:S1:7928:13	O
alfa	VICTRELIS.xml:S1:7942:4	O
and	VICTRELIS.xml:S1:7947:3	O
ribavirin	VICTRELIS.xml:S1:7951:9	O
compared	VICTRELIS.xml:S1:7961:8	O
with	VICTRELIS.xml:S1:7970:4	O
subjects	VICTRELIS.xml:S1:7975:8	O
who	VICTRELIS.xml:S1:7984:3	O
received	VICTRELIS.xml:S1:7988:8	O
only	VICTRELIS.xml:S1:7997:4	O
peginterferon	VICTRELIS.xml:S1:8002:13	O
alfa	VICTRELIS.xml:S1:8016:4	O
and	VICTRELIS.xml:S1:8021:3	O
ribavirin	VICTRELIS.xml:S1:8025:9	O
.	VICTRELIS.xml:S1:8034:1	O

Gastrointestinal	VICTRELIS.xml:S1:8044:16	O
Disorders	VICTRELIS.xml:S1:8061:9	O

Dysgeusia	VICTRELIS.xml:S1:8077:9	B-AdverseReaction
(	VICTRELIS.xml:S1:8087:1	O
alteration	VICTRELIS.xml:S1:8088:10	B-AdverseReaction
of	VICTRELIS.xml:S1:8099:2	I-AdverseReaction
taste	VICTRELIS.xml:S1:8102:5	I-AdverseReaction
)	VICTRELIS.xml:S1:8107:1	O
was	VICTRELIS.xml:S1:8109:3	O
an	VICTRELIS.xml:S1:8113:2	O
adverse	VICTRELIS.xml:S1:8116:7	O
event	VICTRELIS.xml:S1:8124:5	O
reported	VICTRELIS.xml:S1:8130:8	O
at	VICTRELIS.xml:S1:8139:2	O
an	VICTRELIS.xml:S1:8142:2	O
increased	VICTRELIS.xml:S1:8145:9	O
frequency	VICTRELIS.xml:S1:8155:9	O
in	VICTRELIS.xml:S1:8165:2	O
subjects	VICTRELIS.xml:S1:8168:8	O
receiving	VICTRELIS.xml:S1:8177:9	O
VICTRELIS	VICTRELIS.xml:S1:8187:9	O
in	VICTRELIS.xml:S1:8197:2	O
combination	VICTRELIS.xml:S1:8200:11	O
with	VICTRELIS.xml:S1:8212:4	O
peginterferon	VICTRELIS.xml:S1:8217:13	O
alfa	VICTRELIS.xml:S1:8231:4	O
and	VICTRELIS.xml:S1:8236:3	O
ribavirin	VICTRELIS.xml:S1:8240:9	O
compared	VICTRELIS.xml:S1:8250:8	O
with	VICTRELIS.xml:S1:8259:4	O
subjects	VICTRELIS.xml:S1:8264:8	O
receiving	VICTRELIS.xml:S1:8273:9	O
peginterferon	VICTRELIS.xml:S1:8283:13	O
alfa	VICTRELIS.xml:S1:8297:4	O
and	VICTRELIS.xml:S1:8302:3	O
ribavirin	VICTRELIS.xml:S1:8306:9	O
alone	VICTRELIS.xml:S1:8316:5	O
(	VICTRELIS.xml:S1:8322:1	O
Table	VICTRELIS.xml:S1:8325:5	O
3	VICTRELIS.xml:S1:8331:1	O
)	VICTRELIS.xml:S1:8334:1	O
.	VICTRELIS.xml:S1:8335:1	O

Adverse	VICTRELIS.xml:S1:8337:7	O
events	VICTRELIS.xml:S1:8345:6	O
such	VICTRELIS.xml:S1:8352:4	O
as	VICTRELIS.xml:S1:8357:2	O
dry	VICTRELIS.xml:S1:8360:3	B-AdverseReaction
mouth	VICTRELIS.xml:S1:8364:5	I-AdverseReaction
,	VICTRELIS.xml:S1:8369:1	O
nausea	VICTRELIS.xml:S1:8371:6	B-AdverseReaction
,	VICTRELIS.xml:S1:8377:1	O
vomiting	VICTRELIS.xml:S1:8379:8	B-AdverseReaction
and	VICTRELIS.xml:S1:8388:3	O
diarrhea	VICTRELIS.xml:S1:8392:8	B-AdverseReaction
were	VICTRELIS.xml:S1:8401:4	O
also	VICTRELIS.xml:S1:8406:4	O
reported	VICTRELIS.xml:S1:8411:8	O
at	VICTRELIS.xml:S1:8420:2	O
an	VICTRELIS.xml:S1:8423:2	O
increased	VICTRELIS.xml:S1:8426:9	O
frequency	VICTRELIS.xml:S1:8436:9	O
in	VICTRELIS.xml:S1:8446:2	O
subjects	VICTRELIS.xml:S1:8449:8	O
receiving	VICTRELIS.xml:S1:8458:9	O
VICTRELIS	VICTRELIS.xml:S1:8468:9	O
in	VICTRELIS.xml:S1:8478:2	O
combination	VICTRELIS.xml:S1:8481:11	O
with	VICTRELIS.xml:S1:8493:4	O
peginterferon	VICTRELIS.xml:S1:8498:13	O
alfa	VICTRELIS.xml:S1:8512:4	O
and	VICTRELIS.xml:S1:8517:3	O
ribavirin	VICTRELIS.xml:S1:8521:9	O
.	VICTRELIS.xml:S1:8530:1	O

Laboratory	VICTRELIS.xml:S1:8540:10	O
Values	VICTRELIS.xml:S1:8551:6	O

Changes	VICTRELIS.xml:S1:8564:7	O
in	VICTRELIS.xml:S1:8572:2	O
selected	VICTRELIS.xml:S1:8575:8	O
hematological	VICTRELIS.xml:S1:8584:13	O
parameters	VICTRELIS.xml:S1:8598:10	O
during	VICTRELIS.xml:S1:8609:6	O
treatment	VICTRELIS.xml:S1:8616:9	O
of	VICTRELIS.xml:S1:8626:2	O
adult	VICTRELIS.xml:S1:8629:5	O
subjects	VICTRELIS.xml:S1:8635:8	O
with	VICTRELIS.xml:S1:8644:4	O
the	VICTRELIS.xml:S1:8649:3	O
combination	VICTRELIS.xml:S1:8653:11	O
of	VICTRELIS.xml:S1:8665:2	O
VICTRELIS	VICTRELIS.xml:S1:8668:9	O
with	VICTRELIS.xml:S1:8678:4	O
PegIntron	VICTRELIS.xml:S1:8683:9	O
and	VICTRELIS.xml:S1:8693:3	O
REBETOL	VICTRELIS.xml:S1:8697:7	O
are	VICTRELIS.xml:S1:8705:3	O
described	VICTRELIS.xml:S1:8709:9	O
in	VICTRELIS.xml:S1:8719:2	O
Table	VICTRELIS.xml:S1:8723:5	O
4	VICTRELIS.xml:S1:8729:1	O
.	VICTRELIS.xml:S1:8730:1	O

Hemoglobin	VICTRELIS.xml:S1:8742:10	O

Decreases	VICTRELIS.xml:S1:8759:9	O
in	VICTRELIS.xml:S1:8769:2	O
hemoglobin	VICTRELIS.xml:S1:8772:10	O
may	VICTRELIS.xml:S1:8783:3	O
require	VICTRELIS.xml:S1:8787:7	O
a	VICTRELIS.xml:S1:8795:1	O
decrease	VICTRELIS.xml:S1:8797:8	O
in	VICTRELIS.xml:S1:8806:2	O
dosage	VICTRELIS.xml:S1:8809:6	O
or	VICTRELIS.xml:S1:8816:2	O
discontinuation	VICTRELIS.xml:S1:8819:15	O
of	VICTRELIS.xml:S1:8835:2	O
ribavirin	VICTRELIS.xml:S1:8838:9	O
[	VICTRELIS.xml:S1:8849:1	O
see	VICTRELIS.xml:S1:8850:3	O
Warnings	VICTRELIS.xml:S1:8855:8	O
and	VICTRELIS.xml:S1:8864:3	O
Precautions	VICTRELIS.xml:S1:8868:11	O
(	VICTRELIS.xml:S1:8880:1	O
5.2	VICTRELIS.xml:S1:8881:3	O
)	VICTRELIS.xml:S1:8884:1	O
and	VICTRELIS.xml:S1:8887:3	O
Clinical	VICTRELIS.xml:S1:8892:8	O
Studies	VICTRELIS.xml:S1:8901:7	O
(	VICTRELIS.xml:S1:8909:1	O
14	VICTRELIS.xml:S1:8910:2	O
)	VICTRELIS.xml:S1:8912:1	O
]	VICTRELIS.xml:S1:8915:1	O
[	VICTRELIS.xml:S1:8917:1	O
see	VICTRELIS.xml:S1:8918:3	O
prescribing	VICTRELIS.xml:S1:8922:11	O
information	VICTRELIS.xml:S1:8934:11	O
for	VICTRELIS.xml:S1:8946:3	O
ribavirin	VICTRELIS.xml:S1:8950:9	O
]	VICTRELIS.xml:S1:8959:1	O
.	VICTRELIS.xml:S1:8962:1	O

If	VICTRELIS.xml:S1:8964:2	O
ribavirin	VICTRELIS.xml:S1:8967:9	O
is	VICTRELIS.xml:S1:8977:2	O
permanently	VICTRELIS.xml:S1:8980:11	O
discontinued	VICTRELIS.xml:S1:8992:12	O
,	VICTRELIS.xml:S1:9004:1	O
then	VICTRELIS.xml:S1:9006:4	O
peginterferon	VICTRELIS.xml:S1:9011:13	O
alfa	VICTRELIS.xml:S1:9025:4	O
and	VICTRELIS.xml:S1:9030:3	O
VICTRELIS	VICTRELIS.xml:S1:9034:9	O
must	VICTRELIS.xml:S1:9044:4	O
also	VICTRELIS.xml:S1:9049:4	O
be	VICTRELIS.xml:S1:9054:2	O
discontinued	VICTRELIS.xml:S1:9057:12	O
[	VICTRELIS.xml:S1:9071:1	O
see	VICTRELIS.xml:S1:9072:3	O
Dosage	VICTRELIS.xml:S1:9077:6	O
and	VICTRELIS.xml:S1:9084:3	O
Administration	VICTRELIS.xml:S1:9088:14	O
(	VICTRELIS.xml:S1:9103:1	O
2.3	VICTRELIS.xml:S1:9104:3	O
)	VICTRELIS.xml:S1:9107:1	O
]	VICTRELIS.xml:S1:9110:1	O
.	VICTRELIS.xml:S1:9113:1	O

Neutrophils	VICTRELIS.xml:S1:9123:11	O
and	VICTRELIS.xml:S1:9135:3	O
Platelets	VICTRELIS.xml:S1:9139:9	O

The	VICTRELIS.xml:S1:9155:3	O
proportion	VICTRELIS.xml:S1:9159:10	O
of	VICTRELIS.xml:S1:9170:2	O
subjects	VICTRELIS.xml:S1:9173:8	O
with	VICTRELIS.xml:S1:9182:4	O
decreased	VICTRELIS.xml:S1:9187:9	B-AdverseReaction
neutrophil	VICTRELIS.xml:S1:9197:10	I-AdverseReaction
and	VICTRELIS.xml:S1:9208:3	O
platelet	VICTRELIS.xml:S1:9212:8	I-AdverseReaction
counts	VICTRELIS.xml:S1:9221:6	I-AdverseReaction
was	VICTRELIS.xml:S1:9228:3	O
higher	VICTRELIS.xml:S1:9232:6	O
in	VICTRELIS.xml:S1:9239:2	O
subjects	VICTRELIS.xml:S1:9242:8	O
treated	VICTRELIS.xml:S1:9251:7	O
with	VICTRELIS.xml:S1:9259:4	O
VICTRELIS	VICTRELIS.xml:S1:9264:9	O
in	VICTRELIS.xml:S1:9274:2	O
combination	VICTRELIS.xml:S1:9277:11	O
with	VICTRELIS.xml:S1:9289:4	O
PegIntron	VICTRELIS.xml:S1:9294:9	O
REBETOL	VICTRELIS.xml:S1:9304:7	O
compared	VICTRELIS.xml:S1:9312:8	O
to	VICTRELIS.xml:S1:9321:2	O
subjects	VICTRELIS.xml:S1:9324:8	O
receiving	VICTRELIS.xml:S1:9333:9	O
PegIntron	VICTRELIS.xml:S1:9343:9	O
REBETOL	VICTRELIS.xml:S1:9353:7	O
alone	VICTRELIS.xml:S1:9361:5	O
.	VICTRELIS.xml:S1:9366:1	O

Three	VICTRELIS.xml:S1:9368:5	O
percent	VICTRELIS.xml:S1:9374:7	O
of	VICTRELIS.xml:S1:9382:2	O
subjects	VICTRELIS.xml:S1:9385:8	O
receiving	VICTRELIS.xml:S1:9394:9	O
the	VICTRELIS.xml:S1:9404:3	O
combination	VICTRELIS.xml:S1:9408:11	O
of	VICTRELIS.xml:S1:9420:2	O
VICTRELIS	VICTRELIS.xml:S1:9423:9	O
with	VICTRELIS.xml:S1:9433:4	O
PegIntron	VICTRELIS.xml:S1:9438:9	O
REBETOL	VICTRELIS.xml:S1:9448:7	O
had	VICTRELIS.xml:S1:9456:3	O
platelet	VICTRELIS.xml:S1:9460:8	B-AdverseReaction
counts	VICTRELIS.xml:S1:9469:6	I-AdverseReaction
of	VICTRELIS.xml:S1:9476:2	I-AdverseReaction
less	VICTRELIS.xml:S1:9479:4	I-AdverseReaction
than	VICTRELIS.xml:S1:9484:4	I-AdverseReaction
50	VICTRELIS.xml:S1:9489:2	I-AdverseReaction
10	VICTRELIS.xml:S1:9494:2	I-AdverseReaction
9	VICTRELIS.xml:S1:9498:1	I-AdverseReaction
per	VICTRELIS.xml:S1:9501:3	I-AdverseReaction
L	VICTRELIS.xml:S1:9505:1	I-AdverseReaction
compared	VICTRELIS.xml:S1:9507:8	O
to	VICTRELIS.xml:S1:9516:2	O
1%	VICTRELIS.xml:S1:9519:2	O
of	VICTRELIS.xml:S1:9522:2	O
subjects	VICTRELIS.xml:S1:9525:8	O
receiving	VICTRELIS.xml:S1:9534:9	O
PegIntron	VICTRELIS.xml:S1:9544:9	O
REBETOL	VICTRELIS.xml:S1:9554:7	O
alone	VICTRELIS.xml:S1:9562:5	O
.	VICTRELIS.xml:S1:9567:1	O

Decreases	VICTRELIS.xml:S1:9569:9	O
in	VICTRELIS.xml:S1:9579:2	O
neutrophils	VICTRELIS.xml:S1:9582:11	O
or	VICTRELIS.xml:S1:9594:2	O
platelets	VICTRELIS.xml:S1:9597:9	O
may	VICTRELIS.xml:S1:9607:3	O
require	VICTRELIS.xml:S1:9611:7	O
a	VICTRELIS.xml:S1:9619:1	O
decrease	VICTRELIS.xml:S1:9621:8	O
in	VICTRELIS.xml:S1:9630:2	O
dosage	VICTRELIS.xml:S1:9633:6	O
or	VICTRELIS.xml:S1:9640:2	O
interruption	VICTRELIS.xml:S1:9643:12	O
of	VICTRELIS.xml:S1:9656:2	O
peginterferon	VICTRELIS.xml:S1:9659:13	O
alfa	VICTRELIS.xml:S1:9673:4	O
,	VICTRELIS.xml:S1:9677:1	O
or	VICTRELIS.xml:S1:9679:2	O
discontinuation	VICTRELIS.xml:S1:9682:15	O
of	VICTRELIS.xml:S1:9698:2	O
therapy	VICTRELIS.xml:S1:9701:7	O
[	VICTRELIS.xml:S1:9710:1	O
see	VICTRELIS.xml:S1:9711:3	O
prescribing	VICTRELIS.xml:S1:9715:11	O
information	VICTRELIS.xml:S1:9727:11	O
for	VICTRELIS.xml:S1:9739:3	O
peginterferon	VICTRELIS.xml:S1:9743:13	O
alfa	VICTRELIS.xml:S1:9757:4	O
and	VICTRELIS.xml:S1:9762:3	O
ribavirin	VICTRELIS.xml:S1:9766:9	O
]	VICTRELIS.xml:S1:9775:1	O
.	VICTRELIS.xml:S1:9778:1	O

If	VICTRELIS.xml:S1:9780:2	O
peginterferon	VICTRELIS.xml:S1:9783:13	O
alfa	VICTRELIS.xml:S1:9797:4	O
is	VICTRELIS.xml:S1:9802:2	O
permanently	VICTRELIS.xml:S1:9805:11	O
discontinued	VICTRELIS.xml:S1:9817:12	O
,	VICTRELIS.xml:S1:9829:1	O
then	VICTRELIS.xml:S1:9831:4	O
ribavirin	VICTRELIS.xml:S1:9836:9	O
and	VICTRELIS.xml:S1:9846:3	O
VICTRELIS	VICTRELIS.xml:S1:9850:9	O
must	VICTRELIS.xml:S1:9860:4	O
also	VICTRELIS.xml:S1:9865:4	O
be	VICTRELIS.xml:S1:9870:2	O
discontinued	VICTRELIS.xml:S1:9873:12	O
[	VICTRELIS.xml:S1:9887:1	O
see	VICTRELIS.xml:S1:9888:3	O
Dosage	VICTRELIS.xml:S1:9893:6	O
and	VICTRELIS.xml:S1:9900:3	O
Administration	VICTRELIS.xml:S1:9904:14	O
(	VICTRELIS.xml:S1:9919:1	O
2.3	VICTRELIS.xml:S1:9920:3	O
)	VICTRELIS.xml:S1:9923:1	O
]	VICTRELIS.xml:S1:9926:1	O
.	VICTRELIS.xml:S1:9929:1	O

Table	VICTRELIS.xml:S1:9935:5	O
4	VICTRELIS.xml:S1:9941:1	O
Selected	VICTRELIS.xml:S1:9943:8	O
Hematological	VICTRELIS.xml:S1:9952:13	O
Parameters	VICTRELIS.xml:S1:9966:10	O

Previously	VICTRELIS.xml:S1:10005:10	O
Untreated	VICTRELIS.xml:S1:10016:9	O
(	VICTRELIS.xml:S1:10025:1	O
SPRINT	VICTRELIS.xml:S1:10026:6	O
-	VICTRELIS.xml:S1:10032:1	O
1	VICTRELIS.xml:S1:10033:1	O
and	VICTRELIS.xml:S1:10035:3	O
SPRINT	VICTRELIS.xml:S1:10039:6	O
-	VICTRELIS.xml:S1:10045:1	O
2	VICTRELIS.xml:S1:10046:1	O
)	VICTRELIS.xml:S1:10047:1	O
Previous	VICTRELIS.xml:S1:10050:8	O
Treatment	VICTRELIS.xml:S1:10059:9	O
Failures	VICTRELIS.xml:S1:10069:8	O
(	VICTRELIS.xml:S1:10077:1	O
RESPOND	VICTRELIS.xml:S1:10078:7	O
-	VICTRELIS.xml:S1:10085:1	O
2	VICTRELIS.xml:S1:10086:1	O
)	VICTRELIS.xml:S1:10087:1	O

Percentage	VICTRELIS.xml:S1:10119:10	O
of	VICTRELIS.xml:S1:10130:2	O
Subjects	VICTRELIS.xml:S1:10133:8	O
Reporting	VICTRELIS.xml:S1:10142:9	O
Selected	VICTRELIS.xml:S1:10152:8	O
Hematological	VICTRELIS.xml:S1:10161:13	O
Parameters	VICTRELIS.xml:S1:10175:10	O
Percentage	VICTRELIS.xml:S1:10187:10	O
of	VICTRELIS.xml:S1:10198:2	O
Subjects	VICTRELIS.xml:S1:10201:8	O
Reporting	VICTRELIS.xml:S1:10210:9	O
Selected	VICTRELIS.xml:S1:10220:8	O
Hematological	VICTRELIS.xml:S1:10229:13	O
Parameters	VICTRELIS.xml:S1:10243:10	O

Hematological	VICTRELIS.xml:S1:10258:13	O
Parameters	VICTRELIS.xml:S1:10272:10	O
VICTRELIS	VICTRELIS.xml:S1:10284:9	O
PegIntron	VICTRELIS.xml:S1:10296:9	O
REBETOL	VICTRELIS.xml:S1:10308:7	O
(	VICTRELIS.xml:S1:10315:1	O
n	VICTRELIS.xml:S1:10316:1	O
1225	VICTRELIS.xml:S1:10318:4	O
)	VICTRELIS.xml:S1:10322:1	O
PegIntron	VICTRELIS.xml:S1:10325:9	O
REBETOL	VICTRELIS.xml:S1:10337:7	O
(	VICTRELIS.xml:S1:10344:1	O
n	VICTRELIS.xml:S1:10345:1	O
467	VICTRELIS.xml:S1:10347:3	O
)	VICTRELIS.xml:S1:10350:1	O
VICTRELIS	VICTRELIS.xml:S1:10353:9	O
PegIntron	VICTRELIS.xml:S1:10365:9	O
REBETOL	VICTRELIS.xml:S1:10377:7	O
(	VICTRELIS.xml:S1:10384:1	O
n	VICTRELIS.xml:S1:10385:1	O
323	VICTRELIS.xml:S1:10387:3	O
)	VICTRELIS.xml:S1:10390:1	O
PegIntron	VICTRELIS.xml:S1:10393:9	O
REBETOL	VICTRELIS.xml:S1:10405:7	O
(	VICTRELIS.xml:S1:10412:1	O
n	VICTRELIS.xml:S1:10413:1	O
80	VICTRELIS.xml:S1:10415:2	O
)	VICTRELIS.xml:S1:10417:1	O

Hemoglobin	VICTRELIS.xml:S1:10428:10	B-AdverseReaction

(	VICTRELIS.xml:S1:10439:1	I-AdverseReaction
g	VICTRELIS.xml:S1:10440:1	I-AdverseReaction
dL	VICTRELIS.xml:S1:10442:2	I-AdverseReaction
)	VICTRELIS.xml:S1:10444:1	I-AdverseReaction

10	VICTRELIS.xml:S1:10456:2	I-AdverseReaction
49	VICTRELIS.xml:S1:10489:2	O
29	VICTRELIS.xml:S1:10510:2	O
49	VICTRELIS.xml:S1:10531:2	O
25	VICTRELIS.xml:S1:10552:2	O

8.5	VICTRELIS.xml:S1:10569:3	I-AdverseReaction
6	VICTRELIS.xml:S1:10603:1	O
3	VICTRELIS.xml:S1:10624:1	O
10	VICTRELIS.xml:S1:10644:2	O
1	VICTRELIS.xml:S1:10666:1	O

Neutrophils	VICTRELIS.xml:S1:10683:11	B-AdverseReaction
(	VICTRELIS.xml:S1:10695:1	I-AdverseReaction
10	VICTRELIS.xml:S1:10698:2	I-AdverseReaction
9	VICTRELIS.xml:S1:10702:1	I-AdverseReaction
L	VICTRELIS.xml:S1:10706:1	I-AdverseReaction
)	VICTRELIS.xml:S1:10707:1	I-AdverseReaction

0.75	VICTRELIS.xml:S1:10716:4	I-AdverseReaction
31	VICTRELIS.xml:S1:10749:2	O
18	VICTRELIS.xml:S1:10770:2	O
26	VICTRELIS.xml:S1:10791:2	O
13	VICTRELIS.xml:S1:10812:2	O

0.5	VICTRELIS.xml:S1:10829:3	I-AdverseReaction
8	VICTRELIS.xml:S1:10863:1	O
4	VICTRELIS.xml:S1:10884:1	O
7	VICTRELIS.xml:S1:10905:1	O
4	VICTRELIS.xml:S1:10926:1	O

Platelets	VICTRELIS.xml:S1:10943:9	B-AdverseReaction
(	VICTRELIS.xml:S1:10953:1	I-AdverseReaction
10	VICTRELIS.xml:S1:10956:2	I-AdverseReaction
9	VICTRELIS.xml:S1:10960:1	I-AdverseReaction
L	VICTRELIS.xml:S1:10964:1	I-AdverseReaction
)	VICTRELIS.xml:S1:10965:1	I-AdverseReaction

50	VICTRELIS.xml:S1:10974:2	I-AdverseReaction
3	VICTRELIS.xml:S1:11008:1	O
1	VICTRELIS.xml:S1:11029:1	O
4	VICTRELIS.xml:S1:11050:1	O
0	VICTRELIS.xml:S1:11071:1	O

25	VICTRELIS.xml:S1:11087:2	I-AdverseReaction
1	VICTRELIS.xml:S1:11121:1	O
0	VICTRELIS.xml:S1:11142:1	O
0	VICTRELIS.xml:S1:11163:1	O
0	VICTRELIS.xml:S1:11184:1	O

6.2	VICTRELIS.xml:S1:11211:3	O
Postmarketing	VICTRELIS.xml:S1:11215:13	O
Experience	VICTRELIS.xml:S1:11229:10	O

The	VICTRELIS.xml:S1:11243:3	O
following	VICTRELIS.xml:S1:11247:9	O
adverse	VICTRELIS.xml:S1:11257:7	O
reactions	VICTRELIS.xml:S1:11265:9	O
have	VICTRELIS.xml:S1:11275:4	O
been	VICTRELIS.xml:S1:11280:4	O
identified	VICTRELIS.xml:S1:11285:10	O
during	VICTRELIS.xml:S1:11296:6	O
post	VICTRELIS.xml:S1:11303:4	O
-	VICTRELIS.xml:S1:11307:1	O
approval	VICTRELIS.xml:S1:11308:8	O
use	VICTRELIS.xml:S1:11317:3	O
of	VICTRELIS.xml:S1:11321:2	O
VICTRELIS	VICTRELIS.xml:S1:11324:9	O
in	VICTRELIS.xml:S1:11334:2	O
combination	VICTRELIS.xml:S1:11337:11	O
with	VICTRELIS.xml:S1:11349:4	O
peginterferon	VICTRELIS.xml:S1:11354:13	O
alfa	VICTRELIS.xml:S1:11368:4	O
and	VICTRELIS.xml:S1:11373:3	O
ribavirin	VICTRELIS.xml:S1:11377:9	O
.	VICTRELIS.xml:S1:11386:1	O

Because	VICTRELIS.xml:S1:11388:7	O
these	VICTRELIS.xml:S1:11396:5	O
reactions	VICTRELIS.xml:S1:11402:9	O
are	VICTRELIS.xml:S1:11412:3	O
reported	VICTRELIS.xml:S1:11416:8	O
voluntarily	VICTRELIS.xml:S1:11425:11	O
from	VICTRELIS.xml:S1:11437:4	O
a	VICTRELIS.xml:S1:11442:1	O
population	VICTRELIS.xml:S1:11444:10	O
of	VICTRELIS.xml:S1:11455:2	O
uncertain	VICTRELIS.xml:S1:11458:9	O
size	VICTRELIS.xml:S1:11468:4	O
,	VICTRELIS.xml:S1:11472:1	O
it	VICTRELIS.xml:S1:11474:2	O
is	VICTRELIS.xml:S1:11477:2	O
not	VICTRELIS.xml:S1:11480:3	O
always	VICTRELIS.xml:S1:11484:6	O
possible	VICTRELIS.xml:S1:11491:8	O
to	VICTRELIS.xml:S1:11500:2	O
reliably	VICTRELIS.xml:S1:11503:8	O
estimate	VICTRELIS.xml:S1:11512:8	O
their	VICTRELIS.xml:S1:11521:5	O
frequency	VICTRELIS.xml:S1:11527:9	O
or	VICTRELIS.xml:S1:11537:2	O
establish	VICTRELIS.xml:S1:11540:9	O
a	VICTRELIS.xml:S1:11550:1	O
causal	VICTRELIS.xml:S1:11552:6	O
relationship	VICTRELIS.xml:S1:11559:12	O
to	VICTRELIS.xml:S1:11572:2	O
drug	VICTRELIS.xml:S1:11575:4	O
exposure	VICTRELIS.xml:S1:11580:8	O
.	VICTRELIS.xml:S1:11588:1	O

Blood	VICTRELIS.xml:S1:11596:5	O
and	VICTRELIS.xml:S1:11602:3	O
Lymphatic	VICTRELIS.xml:S1:11606:9	O
System	VICTRELIS.xml:S1:11616:6	O
Disorders	VICTRELIS.xml:S1:11623:9	O
:	VICTRELIS.xml:S1:11632:1	O
agranulocytosis	VICTRELIS.xml:S1:11635:15	B-AdverseReaction
,	VICTRELIS.xml:S1:11650:1	O
pancytopenia	VICTRELIS.xml:S1:11652:12	B-AdverseReaction
,	VICTRELIS.xml:S1:11666:1	O
thrombocytopenia	VICTRELIS.xml:S1:11669:16	B-AdverseReaction
[	VICTRELIS.xml:S1:11687:1	O
see	VICTRELIS.xml:S1:11688:3	O
Warnings	VICTRELIS.xml:S1:11693:8	O
and	VICTRELIS.xml:S1:11702:3	O
Precautions	VICTRELIS.xml:S1:11706:11	O
(	VICTRELIS.xml:S1:11718:1	O
5.4	VICTRELIS.xml:S1:11719:3	O
)	VICTRELIS.xml:S1:11722:1	O
]	VICTRELIS.xml:S1:11725:1	O

Gastrointestinal	VICTRELIS.xml:S1:11735:16	O
Disorders	VICTRELIS.xml:S1:11752:9	O
:	VICTRELIS.xml:S1:11761:1	O
mouth	VICTRELIS.xml:S1:11764:5	B-AdverseReaction
ulceration	VICTRELIS.xml:S1:11770:10	I-AdverseReaction
,	VICTRELIS.xml:S1:11780:1	O
stomatitis	VICTRELIS.xml:S1:11782:10	B-AdverseReaction

Infections	VICTRELIS.xml:S1:11799:10	O
and	VICTRELIS.xml:S1:11810:3	O
Infestations	VICTRELIS.xml:S1:11814:12	O
:	VICTRELIS.xml:S1:11826:1	O
pneumonia	VICTRELIS.xml:S1:11829:9	B-AdverseReaction
,	VICTRELIS.xml:S1:11838:1	O
sepsis	VICTRELIS.xml:S1:11840:6	B-AdverseReaction

Skin	VICTRELIS.xml:S1:11853:4	O
and	VICTRELIS.xml:S1:11858:3	O
Subcutaneous	VICTRELIS.xml:S1:11862:12	O
Tissue	VICTRELIS.xml:S1:11875:6	O
Disorders	VICTRELIS.xml:S1:11882:9	O
:	VICTRELIS.xml:S1:11891:1	O
angioedema	VICTRELIS.xml:S1:11894:10	B-AdverseReaction
,	VICTRELIS.xml:S1:11904:1	O
urticaria	VICTRELIS.xml:S1:11906:9	B-AdverseReaction
[	VICTRELIS.xml:S1:11917:1	O
see	VICTRELIS.xml:S1:11918:3	O
Warnings	VICTRELIS.xml:S1:11923:8	O
and	VICTRELIS.xml:S1:11932:3	O
Precautions	VICTRELIS.xml:S1:11936:11	O
(	VICTRELIS.xml:S1:11948:1	O
5.5	VICTRELIS.xml:S1:11949:3	O
)	VICTRELIS.xml:S1:11952:1	O
]	VICTRELIS.xml:S1:11955:1	O
;	VICTRELIS.xml:S1:11958:1	O
drug	VICTRELIS.xml:S1:11960:4	B-AdverseReaction
rash	VICTRELIS.xml:S1:11965:4	I-AdverseReaction
with	VICTRELIS.xml:S1:11970:4	I-AdverseReaction
eosinophilia	VICTRELIS.xml:S1:11975:12	I-AdverseReaction
and	VICTRELIS.xml:S1:11988:3	I-AdverseReaction
systemic	VICTRELIS.xml:S1:11992:8	I-AdverseReaction
symptoms	VICTRELIS.xml:S1:12001:8	I-AdverseReaction
(	VICTRELIS.xml:S1:12010:1	O
DRESS	VICTRELIS.xml:S1:12011:5	B-AdverseReaction
)	VICTRELIS.xml:S1:12016:1	O
syndrome	VICTRELIS.xml:S1:12018:8	I-AdverseReaction
,	VICTRELIS.xml:S1:12026:1	O
exfoliative	VICTRELIS.xml:S1:12028:11	B-AdverseReaction
rash	VICTRELIS.xml:S1:12040:4	I-AdverseReaction
,	VICTRELIS.xml:S1:12044:1	O
exfoliative	VICTRELIS.xml:S1:12046:11	B-AdverseReaction
dermatitis	VICTRELIS.xml:S1:12058:10	I-AdverseReaction
,	VICTRELIS.xml:S1:12068:1	O
Stevens	VICTRELIS.xml:S1:12070:7	B-AdverseReaction
-	VICTRELIS.xml:S1:12077:1	I-AdverseReaction
Johnson	VICTRELIS.xml:S1:12078:7	I-AdverseReaction
syndrome	VICTRELIS.xml:S1:12086:8	I-AdverseReaction
,	VICTRELIS.xml:S1:12094:1	O
toxic	VICTRELIS.xml:S1:12096:5	B-AdverseReaction
skin	VICTRELIS.xml:S1:12102:4	I-AdverseReaction
eruption	VICTRELIS.xml:S1:12107:8	I-AdverseReaction
,	VICTRELIS.xml:S1:12115:1	O
toxicoderma	VICTRELIS.xml:S1:12117:11	B-AdverseReaction
5	VICTRELIS.xml:S2:4:1	O
WARNINGS	VICTRELIS.xml:S2:6:8	O
AND	VICTRELIS.xml:S2:15:3	O
PRECAUTIONS	VICTRELIS.xml:S2:19:11	O

EXCERPT	VICTRELIS.xml:S2:36:7	O
:	VICTRELIS.xml:S2:43:1	O
Use	VICTRELIS.xml:S2:48:3	O
of	VICTRELIS.xml:S2:52:2	O
VICTRELIS	VICTRELIS.xml:S2:55:9	O
with	VICTRELIS.xml:S2:65:4	O
Ribavirin	VICTRELIS.xml:S2:70:9	O
and	VICTRELIS.xml:S2:80:3	O
Peginterferon	VICTRELIS.xml:S2:84:13	O
alfa	VICTRELIS.xml:S2:98:4	O
:	VICTRELIS.xml:S2:102:1	O

Embryofetal	VICTRELIS.xml:S2:114:11	B-AdverseReaction
Toxicity	VICTRELIS.xml:S2:126:8	I-AdverseReaction
(	VICTRELIS.xml:S2:135:1	O
Use	VICTRELIS.xml:S2:136:3	O
with	VICTRELIS.xml:S2:140:4	O
Ribavirin	VICTRELIS.xml:S2:145:9	O
and	VICTRELIS.xml:S2:155:3	O
Peginterferon	VICTRELIS.xml:S2:159:13	O
Alfa	VICTRELIS.xml:S2:173:4	O
)	VICTRELIS.xml:S2:177:1	O
:	VICTRELIS.xml:S2:178:1	O
Ribavirin	VICTRELIS.xml:S2:180:9	O
may	VICTRELIS.xml:S2:190:3	B-Factor
cause	VICTRELIS.xml:S2:194:5	O
birth	VICTRELIS.xml:S2:200:5	B-AdverseReaction
defects	VICTRELIS.xml:S2:206:7	I-AdverseReaction
and	VICTRELIS.xml:S2:214:3	O
fetal	VICTRELIS.xml:S2:218:5	B-AdverseReaction
death	VICTRELIS.xml:S2:224:5	I-AdverseReaction
;	VICTRELIS.xml:S2:229:1	O
avoid	VICTRELIS.xml:S2:231:5	O
pregnancy	VICTRELIS.xml:S2:237:9	O
in	VICTRELIS.xml:S2:247:2	O
female	VICTRELIS.xml:S2:250:6	O
patients	VICTRELIS.xml:S2:257:8	O
and	VICTRELIS.xml:S2:266:3	O
female	VICTRELIS.xml:S2:270:6	O
partners	VICTRELIS.xml:S2:277:8	O
of	VICTRELIS.xml:S2:286:2	O
male	VICTRELIS.xml:S2:289:4	O
patients	VICTRELIS.xml:S2:294:8	O
.	VICTRELIS.xml:S2:302:1	O

Patients	VICTRELIS.xml:S2:304:8	O
must	VICTRELIS.xml:S2:313:4	O
have	VICTRELIS.xml:S2:318:4	O
a	VICTRELIS.xml:S2:323:1	O
negative	VICTRELIS.xml:S2:325:8	O
pregnancy	VICTRELIS.xml:S2:334:9	O
test	VICTRELIS.xml:S2:344:4	O
prior	VICTRELIS.xml:S2:349:5	O
to	VICTRELIS.xml:S2:355:2	O
therapy	VICTRELIS.xml:S2:358:7	O
;	VICTRELIS.xml:S2:365:1	O
use	VICTRELIS.xml:S2:367:3	O
two	VICTRELIS.xml:S2:371:3	O
or	VICTRELIS.xml:S2:375:2	O
more	VICTRELIS.xml:S2:378:4	O
forms	VICTRELIS.xml:S2:383:5	O
of	VICTRELIS.xml:S2:389:2	O
contraception	VICTRELIS.xml:S2:392:13	O
,	VICTRELIS.xml:S2:405:1	O
and	VICTRELIS.xml:S2:407:3	O
have	VICTRELIS.xml:S2:411:4	O
monthly	VICTRELIS.xml:S2:416:7	O
pregnancy	VICTRELIS.xml:S2:424:9	O
tests	VICTRELIS.xml:S2:434:5	O
.	VICTRELIS.xml:S2:439:1	O

(	VICTRELIS.xml:S2:441:1	O
5.1	VICTRELIS.xml:S2:444:3	O
)	VICTRELIS.xml:S2:449:1	O

Anemia	VICTRELIS.xml:S2:456:6	B-AdverseReaction
-	VICTRELIS.xml:S2:463:1	O
The	VICTRELIS.xml:S2:465:3	O
addition	VICTRELIS.xml:S2:469:8	O
of	VICTRELIS.xml:S2:478:2	O
VICTRELIS	VICTRELIS.xml:S2:481:9	O
to	VICTRELIS.xml:S2:491:2	O
peginterferon	VICTRELIS.xml:S2:494:13	O
alfa	VICTRELIS.xml:S2:508:4	O
and	VICTRELIS.xml:S2:513:3	O
ribavirin	VICTRELIS.xml:S2:517:9	O
is	VICTRELIS.xml:S2:527:2	O
associated	VICTRELIS.xml:S2:530:10	O
with	VICTRELIS.xml:S2:541:4	O
an	VICTRELIS.xml:S2:546:2	O
additional	VICTRELIS.xml:S2:549:10	O
decrease	VICTRELIS.xml:S2:560:8	B-AdverseReaction
in	VICTRELIS.xml:S2:569:2	I-AdverseReaction
hemoglobin	VICTRELIS.xml:S2:572:10	I-AdverseReaction
concentrations	VICTRELIS.xml:S2:583:14	I-AdverseReaction
compared	VICTRELIS.xml:S2:598:8	O
with	VICTRELIS.xml:S2:607:4	O
peginterferon	VICTRELIS.xml:S2:612:13	O
alfa	VICTRELIS.xml:S2:626:4	O
and	VICTRELIS.xml:S2:631:3	O
ribavirin	VICTRELIS.xml:S2:635:9	O
alone	VICTRELIS.xml:S2:645:5	O
.	VICTRELIS.xml:S2:650:1	O

(	VICTRELIS.xml:S2:652:1	O
5.2	VICTRELIS.xml:S2:655:3	O
)	VICTRELIS.xml:S2:660:1	O

Neutropenia	VICTRELIS.xml:S2:667:11	B-AdverseReaction
-	VICTRELIS.xml:S2:679:1	O
The	VICTRELIS.xml:S2:681:3	O
addition	VICTRELIS.xml:S2:685:8	O
of	VICTRELIS.xml:S2:694:2	O
VICTRELIS	VICTRELIS.xml:S2:697:9	O
to	VICTRELIS.xml:S2:707:2	O
peginterferon	VICTRELIS.xml:S2:710:13	O
alfa	VICTRELIS.xml:S2:724:4	O
and	VICTRELIS.xml:S2:729:3	O
ribavirin	VICTRELIS.xml:S2:733:9	O
may	VICTRELIS.xml:S2:743:3	B-Factor
result	VICTRELIS.xml:S2:747:6	O
in	VICTRELIS.xml:S2:754:2	O
worsening	VICTRELIS.xml:S2:757:9	B-AdverseReaction
of	VICTRELIS.xml:S2:767:2	I-AdverseReaction
neutropenia	VICTRELIS.xml:S2:770:11	I-AdverseReaction
associated	VICTRELIS.xml:S2:782:10	O
with	VICTRELIS.xml:S2:793:4	O
peginterferon	VICTRELIS.xml:S2:798:13	O
alfa	VICTRELIS.xml:S2:812:4	O
and	VICTRELIS.xml:S2:817:3	O
ribavirin	VICTRELIS.xml:S2:821:9	O
therapy	VICTRELIS.xml:S2:831:7	O
alone	VICTRELIS.xml:S2:839:5	O
.	VICTRELIS.xml:S2:844:1	O

(	VICTRELIS.xml:S2:846:1	O
5.3	VICTRELIS.xml:S2:849:3	O
)	VICTRELIS.xml:S2:854:1	O

Hypersensitivity	VICTRELIS.xml:S2:861:16	B-AdverseReaction
-	VICTRELIS.xml:S2:878:1	O
Serious	VICTRELIS.xml:S2:880:7	B-Severity
acute	VICTRELIS.xml:S2:888:5	B-AdverseReaction
hypersensitivity	VICTRELIS.xml:S2:894:16	I-AdverseReaction
reactions	VICTRELIS.xml:S2:911:9	I-AdverseReaction
(	VICTRELIS.xml:S2:921:1	O
e	VICTRELIS.xml:S2:922:1	O
.	VICTRELIS.xml:S2:923:1	O
g	VICTRELIS.xml:S2:924:1	O
.	VICTRELIS.xml:S2:925:1	O
,	VICTRELIS.xml:S2:926:1	O
urticaria	VICTRELIS.xml:S2:928:9	B-AdverseReaction
,	VICTRELIS.xml:S2:937:1	O
angioedema	VICTRELIS.xml:S2:939:10	B-AdverseReaction
)	VICTRELIS.xml:S2:949:1	O
have	VICTRELIS.xml:S2:951:4	O
been	VICTRELIS.xml:S2:956:4	O
observed	VICTRELIS.xml:S2:961:8	O
during	VICTRELIS.xml:S2:970:6	O
combination	VICTRELIS.xml:S2:977:11	O
therapy	VICTRELIS.xml:S2:989:7	O
with	VICTRELIS.xml:S2:997:4	O
VICTRELIS	VICTRELIS.xml:S2:1002:9	O
,	VICTRELIS.xml:S2:1011:1	O
peginterferon	VICTRELIS.xml:S2:1013:13	O
alfa	VICTRELIS.xml:S2:1027:4	O
and	VICTRELIS.xml:S2:1032:3	O
ribavirin	VICTRELIS.xml:S2:1036:9	O
.	VICTRELIS.xml:S2:1045:1	O

(	VICTRELIS.xml:S2:1047:1	O
5.5	VICTRELIS.xml:S2:1050:3	O
)	VICTRELIS.xml:S2:1055:1	O

5.1	VICTRELIS.xml:S2:1069:3	O

Embryofetal	VICTRELIS.xml:S2:1073:11	O

Toxicity	VICTRELIS.xml:S2:1085:8	O
(	VICTRELIS.xml:S2:1094:1	O
Use	VICTRELIS.xml:S2:1095:3	O
with	VICTRELIS.xml:S2:1099:4	O
Ribavirin	VICTRELIS.xml:S2:1104:9	O
and	VICTRELIS.xml:S2:1114:3	O
Peginterferon	VICTRELIS.xml:S2:1118:13	O
Alfa	VICTRELIS.xml:S2:1132:4	O
)	VICTRELIS.xml:S2:1136:1	O

Ribavirin	VICTRELIS.xml:S2:1143:9	O
may	VICTRELIS.xml:S2:1153:3	B-Factor
cause	VICTRELIS.xml:S2:1157:5	O
birth	VICTRELIS.xml:S2:1163:5	B-AdverseReaction
defects	VICTRELIS.xml:S2:1169:7	I-AdverseReaction
and	VICTRELIS.xml:S2:1177:3	O
or	VICTRELIS.xml:S2:1181:2	O
death	VICTRELIS.xml:S2:1184:5	B-AdverseReaction
of	VICTRELIS.xml:S2:1190:2	I-AdverseReaction
the	VICTRELIS.xml:S2:1193:3	I-AdverseReaction
exposed	VICTRELIS.xml:S2:1197:7	I-AdverseReaction
fetus	VICTRELIS.xml:S2:1205:5	I-AdverseReaction
.	VICTRELIS.xml:S2:1210:1	O

Extreme	VICTRELIS.xml:S2:1212:7	O
care	VICTRELIS.xml:S2:1220:4	O
must	VICTRELIS.xml:S2:1225:4	O
be	VICTRELIS.xml:S2:1230:2	O
taken	VICTRELIS.xml:S2:1233:5	O
to	VICTRELIS.xml:S2:1239:2	O
avoid	VICTRELIS.xml:S2:1242:5	O
pregnancy	VICTRELIS.xml:S2:1248:9	O
in	VICTRELIS.xml:S2:1258:2	O
female	VICTRELIS.xml:S2:1261:6	O
patients	VICTRELIS.xml:S2:1268:8	O
and	VICTRELIS.xml:S2:1277:3	O
in	VICTRELIS.xml:S2:1281:2	O
female	VICTRELIS.xml:S2:1284:6	O
partners	VICTRELIS.xml:S2:1291:8	O
of	VICTRELIS.xml:S2:1300:2	O
male	VICTRELIS.xml:S2:1303:4	O
patients	VICTRELIS.xml:S2:1308:8	O
.	VICTRELIS.xml:S2:1316:1	O

Ribavirin	VICTRELIS.xml:S2:1318:9	O
therapy	VICTRELIS.xml:S2:1328:7	O
should	VICTRELIS.xml:S2:1336:6	O
not	VICTRELIS.xml:S2:1343:3	O
be	VICTRELIS.xml:S2:1347:2	O
started	VICTRELIS.xml:S2:1350:7	O
unless	VICTRELIS.xml:S2:1358:6	O
a	VICTRELIS.xml:S2:1365:1	O
report	VICTRELIS.xml:S2:1367:6	O
of	VICTRELIS.xml:S2:1374:2	O
a	VICTRELIS.xml:S2:1377:1	O
negative	VICTRELIS.xml:S2:1379:8	O
pregnancy	VICTRELIS.xml:S2:1388:9	O
test	VICTRELIS.xml:S2:1398:4	O
has	VICTRELIS.xml:S2:1403:3	O
been	VICTRELIS.xml:S2:1407:4	O
obtained	VICTRELIS.xml:S2:1412:8	O
immediately	VICTRELIS.xml:S2:1421:11	O
prior	VICTRELIS.xml:S2:1433:5	O
to	VICTRELIS.xml:S2:1439:2	O
initiation	VICTRELIS.xml:S2:1442:10	O
of	VICTRELIS.xml:S2:1453:2	O
therapy	VICTRELIS.xml:S2:1456:7	O
.	VICTRELIS.xml:S2:1463:1	O

Refer	VICTRELIS.xml:S2:1465:5	O
to	VICTRELIS.xml:S2:1471:2	O
the	VICTRELIS.xml:S2:1474:3	O
prescribing	VICTRELIS.xml:S2:1478:11	O
information	VICTRELIS.xml:S2:1490:11	O
for	VICTRELIS.xml:S2:1502:3	O
ribavirin	VICTRELIS.xml:S2:1506:9	O
for	VICTRELIS.xml:S2:1516:3	O
additional	VICTRELIS.xml:S2:1520:10	O
information	VICTRELIS.xml:S2:1531:11	O
.	VICTRELIS.xml:S2:1542:1	O

Women	VICTRELIS.xml:S2:1548:5	O
of	VICTRELIS.xml:S2:1554:2	O
childbearing	VICTRELIS.xml:S2:1557:12	O
potential	VICTRELIS.xml:S2:1570:9	O
and	VICTRELIS.xml:S2:1580:3	O
men	VICTRELIS.xml:S2:1584:3	O
must	VICTRELIS.xml:S2:1588:4	O
use	VICTRELIS.xml:S2:1593:3	O
at	VICTRELIS.xml:S2:1597:2	O
least	VICTRELIS.xml:S2:1600:5	O
two	VICTRELIS.xml:S2:1606:3	O
forms	VICTRELIS.xml:S2:1610:5	O
of	VICTRELIS.xml:S2:1616:2	O
effective	VICTRELIS.xml:S2:1619:9	O
contraception	VICTRELIS.xml:S2:1629:13	O
during	VICTRELIS.xml:S2:1643:6	O
treatment	VICTRELIS.xml:S2:1650:9	O
and	VICTRELIS.xml:S2:1660:3	O
for	VICTRELIS.xml:S2:1664:3	O
at	VICTRELIS.xml:S2:1668:2	O
least	VICTRELIS.xml:S2:1671:5	O
6	VICTRELIS.xml:S2:1677:1	O
months	VICTRELIS.xml:S2:1679:6	O
after	VICTRELIS.xml:S2:1686:5	O
treatment	VICTRELIS.xml:S2:1692:9	O
has	VICTRELIS.xml:S2:1702:3	O
concluded	VICTRELIS.xml:S2:1706:9	O
.	VICTRELIS.xml:S2:1715:1	O

One	VICTRELIS.xml:S2:1717:3	O
of	VICTRELIS.xml:S2:1721:2	O
these	VICTRELIS.xml:S2:1724:5	O
forms	VICTRELIS.xml:S2:1730:5	O
of	VICTRELIS.xml:S2:1736:2	O
contraception	VICTRELIS.xml:S2:1739:13	O
can	VICTRELIS.xml:S2:1753:3	O
be	VICTRELIS.xml:S2:1757:2	O
a	VICTRELIS.xml:S2:1760:1	O
combined	VICTRELIS.xml:S2:1762:8	O
oral	VICTRELIS.xml:S2:1771:4	O
contraceptive	VICTRELIS.xml:S2:1776:13	O
product	VICTRELIS.xml:S2:1790:7	O
containing	VICTRELIS.xml:S2:1798:10	O
at	VICTRELIS.xml:S2:1809:2	O
least	VICTRELIS.xml:S2:1812:5	O
1	VICTRELIS.xml:S2:1818:1	O
mg	VICTRELIS.xml:S2:1820:2	O
of	VICTRELIS.xml:S2:1823:2	O
norethindrone	VICTRELIS.xml:S2:1826:13	O
.	VICTRELIS.xml:S2:1839:1	O

Oral	VICTRELIS.xml:S2:1841:4	O
contraceptives	VICTRELIS.xml:S2:1846:14	O
containing	VICTRELIS.xml:S2:1861:10	O
lower	VICTRELIS.xml:S2:1872:5	O
doses	VICTRELIS.xml:S2:1878:5	O
of	VICTRELIS.xml:S2:1884:2	O
norethindrone	VICTRELIS.xml:S2:1887:13	O
and	VICTRELIS.xml:S2:1901:3	O
other	VICTRELIS.xml:S2:1905:5	O
forms	VICTRELIS.xml:S2:1911:5	O
of	VICTRELIS.xml:S2:1917:2	O
hormonal	VICTRELIS.xml:S2:1920:8	O
contraception	VICTRELIS.xml:S2:1929:13	O
have	VICTRELIS.xml:S2:1943:4	O
not	VICTRELIS.xml:S2:1948:3	O
been	VICTRELIS.xml:S2:1952:4	O
studied	VICTRELIS.xml:S2:1957:7	O
or	VICTRELIS.xml:S2:1965:2	O
are	VICTRELIS.xml:S2:1968:3	O
contraindicated	VICTRELIS.xml:S2:1972:15	O
.	VICTRELIS.xml:S2:1987:1	O

Routine	VICTRELIS.xml:S2:1989:7	O
monthly	VICTRELIS.xml:S2:1997:7	O
pregnancy	VICTRELIS.xml:S2:2005:9	O
tests	VICTRELIS.xml:S2:2015:5	O
must	VICTRELIS.xml:S2:2021:4	O
be	VICTRELIS.xml:S2:2026:2	O
performed	VICTRELIS.xml:S2:2029:9	O
during	VICTRELIS.xml:S2:2039:6	O
this	VICTRELIS.xml:S2:2046:4	O
time	VICTRELIS.xml:S2:2051:4	O
[	VICTRELIS.xml:S2:2056:1	O
see	VICTRELIS.xml:S2:2057:3	O
Contraindications	VICTRELIS.xml:S2:2062:17	O
(	VICTRELIS.xml:S2:2080:1	O
4	VICTRELIS.xml:S2:2081:1	O
)	VICTRELIS.xml:S2:2082:1	O
and	VICTRELIS.xml:S2:2085:3	O
Drug	VICTRELIS.xml:S2:2090:4	O
Interactions	VICTRELIS.xml:S2:2095:12	O
(	VICTRELIS.xml:S2:2108:1	O
7	VICTRELIS.xml:S2:2109:1	O
)	VICTRELIS.xml:S2:2110:1	O
]	VICTRELIS.xml:S2:2113:1	O
.	VICTRELIS.xml:S2:2116:1	O

5.2	VICTRELIS.xml:S2:2125:3	O
Anemia	VICTRELIS.xml:S2:2129:6	O
(	VICTRELIS.xml:S2:2136:1	O
Use	VICTRELIS.xml:S2:2137:3	O
with	VICTRELIS.xml:S2:2141:4	O
Ribavirin	VICTRELIS.xml:S2:2146:9	O
and	VICTRELIS.xml:S2:2156:3	O
Peginterferon	VICTRELIS.xml:S2:2160:13	O
Alfa	VICTRELIS.xml:S2:2174:4	O
)	VICTRELIS.xml:S2:2178:1	O

Anemia	VICTRELIS.xml:S2:2185:6	B-AdverseReaction
has	VICTRELIS.xml:S2:2192:3	O
been	VICTRELIS.xml:S2:2196:4	O
reported	VICTRELIS.xml:S2:2201:8	O
with	VICTRELIS.xml:S2:2210:4	O
peginterferon	VICTRELIS.xml:S2:2215:13	O
alfa	VICTRELIS.xml:S2:2229:4	O
and	VICTRELIS.xml:S2:2234:3	O
ribavirin	VICTRELIS.xml:S2:2238:9	O
therapy	VICTRELIS.xml:S2:2248:7	O
.	VICTRELIS.xml:S2:2255:1	O

The	VICTRELIS.xml:S2:2257:3	O
addition	VICTRELIS.xml:S2:2261:8	O
of	VICTRELIS.xml:S2:2270:2	O
VICTRELIS	VICTRELIS.xml:S2:2273:9	O
to	VICTRELIS.xml:S2:2283:2	O
peginterferon	VICTRELIS.xml:S2:2286:13	O
alfa	VICTRELIS.xml:S2:2300:4	O
and	VICTRELIS.xml:S2:2305:3	O
ribavirin	VICTRELIS.xml:S2:2309:9	O
is	VICTRELIS.xml:S2:2319:2	O
associated	VICTRELIS.xml:S2:2322:10	O
with	VICTRELIS.xml:S2:2333:4	O
an	VICTRELIS.xml:S2:2338:2	O
additional	VICTRELIS.xml:S2:2341:10	B-AdverseReaction
decrease	VICTRELIS.xml:S2:2352:8	I-AdverseReaction
in	VICTRELIS.xml:S2:2361:2	I-AdverseReaction
hemoglobin	VICTRELIS.xml:S2:2364:10	I-AdverseReaction
concentrations	VICTRELIS.xml:S2:2375:14	I-AdverseReaction
.	VICTRELIS.xml:S2:2389:1	O

Complete	VICTRELIS.xml:S2:2391:8	O
blood	VICTRELIS.xml:S2:2400:5	O
counts	VICTRELIS.xml:S2:2406:6	O
(	VICTRELIS.xml:S2:2413:1	O
with	VICTRELIS.xml:S2:2414:4	O
white	VICTRELIS.xml:S2:2419:5	O
blood	VICTRELIS.xml:S2:2425:5	O
cell	VICTRELIS.xml:S2:2431:4	O
differential	VICTRELIS.xml:S2:2436:12	O
counts	VICTRELIS.xml:S2:2449:6	O
)	VICTRELIS.xml:S2:2455:1	O
should	VICTRELIS.xml:S2:2457:6	O
be	VICTRELIS.xml:S2:2464:2	O
obtained	VICTRELIS.xml:S2:2467:8	O
pretreatment	VICTRELIS.xml:S2:2476:12	O
,	VICTRELIS.xml:S2:2488:1	O
and	VICTRELIS.xml:S2:2490:3	O
at	VICTRELIS.xml:S2:2494:2	O
Treatment	VICTRELIS.xml:S2:2497:9	O
Weeks	VICTRELIS.xml:S2:2507:5	O
2	VICTRELIS.xml:S2:2513:1	O
,	VICTRELIS.xml:S2:2514:1	O
4	VICTRELIS.xml:S2:2516:1	O
,	VICTRELIS.xml:S2:2517:1	O
8	VICTRELIS.xml:S2:2519:1	O
,	VICTRELIS.xml:S2:2520:1	O
and	VICTRELIS.xml:S2:2522:3	O
12	VICTRELIS.xml:S2:2526:2	O
,	VICTRELIS.xml:S2:2528:1	O
and	VICTRELIS.xml:S2:2530:3	O
should	VICTRELIS.xml:S2:2534:6	O
be	VICTRELIS.xml:S2:2541:2	O
monitored	VICTRELIS.xml:S2:2544:9	O
closely	VICTRELIS.xml:S2:2554:7	O
at	VICTRELIS.xml:S2:2562:2	O
other	VICTRELIS.xml:S2:2565:5	O
time	VICTRELIS.xml:S2:2571:4	O
points	VICTRELIS.xml:S2:2576:6	O
,	VICTRELIS.xml:S2:2582:1	O
as	VICTRELIS.xml:S2:2584:2	O
clinically	VICTRELIS.xml:S2:2587:10	O
appropriate	VICTRELIS.xml:S2:2598:11	O
.	VICTRELIS.xml:S2:2609:1	O

If	VICTRELIS.xml:S2:2611:2	O
hemoglobin	VICTRELIS.xml:S2:2614:10	O
is	VICTRELIS.xml:S2:2625:2	O
less	VICTRELIS.xml:S2:2628:4	O
than	VICTRELIS.xml:S2:2633:4	O
10	VICTRELIS.xml:S2:2638:2	O
g	VICTRELIS.xml:S2:2641:1	O
per	VICTRELIS.xml:S2:2643:3	O
dL	VICTRELIS.xml:S2:2647:2	O
,	VICTRELIS.xml:S2:2649:1	O
a	VICTRELIS.xml:S2:2651:1	O
decrease	VICTRELIS.xml:S2:2653:8	O
in	VICTRELIS.xml:S2:2662:2	O
dosage	VICTRELIS.xml:S2:2665:6	O
of	VICTRELIS.xml:S2:2672:2	O
ribavirin	VICTRELIS.xml:S2:2675:9	O
is	VICTRELIS.xml:S2:2685:2	O
recommended	VICTRELIS.xml:S2:2688:11	O
;	VICTRELIS.xml:S2:2699:1	O
and	VICTRELIS.xml:S2:2701:3	O
if	VICTRELIS.xml:S2:2705:2	O
hemoglobin	VICTRELIS.xml:S2:2708:10	O
is	VICTRELIS.xml:S2:2719:2	O
less	VICTRELIS.xml:S2:2722:4	O
than	VICTRELIS.xml:S2:2727:4	O
8.5	VICTRELIS.xml:S2:2732:3	O
g	VICTRELIS.xml:S2:2736:1	O
per	VICTRELIS.xml:S2:2738:3	O
dL	VICTRELIS.xml:S2:2742:2	O
,	VICTRELIS.xml:S2:2744:1	O
discontinuation	VICTRELIS.xml:S2:2746:15	O
of	VICTRELIS.xml:S2:2762:2	O
ribavirin	VICTRELIS.xml:S2:2765:9	O
is	VICTRELIS.xml:S2:2775:2	O
recommended	VICTRELIS.xml:S2:2778:11	O
[	VICTRELIS.xml:S2:2790:1	O
see	VICTRELIS.xml:S2:2791:3	O
Adverse	VICTRELIS.xml:S2:2796:7	O
Reactions	VICTRELIS.xml:S2:2804:9	O
(	VICTRELIS.xml:S2:2814:1	O
6.1	VICTRELIS.xml:S2:2815:3	O
)	VICTRELIS.xml:S2:2818:1	O
and	VICTRELIS.xml:S2:2821:3	O
Clinical	VICTRELIS.xml:S2:2826:8	O
Studies	VICTRELIS.xml:S2:2835:7	O
(	VICTRELIS.xml:S2:2843:1	O
14	VICTRELIS.xml:S2:2844:2	O
)	VICTRELIS.xml:S2:2846:1	O
]	VICTRELIS.xml:S2:2849:1	O
.	VICTRELIS.xml:S2:2852:1	O

If	VICTRELIS.xml:S2:2854:2	O
ribavirin	VICTRELIS.xml:S2:2857:9	O
is	VICTRELIS.xml:S2:2867:2	O
permanently	VICTRELIS.xml:S2:2870:11	O
discontinued	VICTRELIS.xml:S2:2882:12	O
for	VICTRELIS.xml:S2:2895:3	O
management	VICTRELIS.xml:S2:2899:10	O
of	VICTRELIS.xml:S2:2910:2	O
anemia	VICTRELIS.xml:S2:2913:6	O
,	VICTRELIS.xml:S2:2919:1	O
then	VICTRELIS.xml:S2:2921:4	O
peginterferon	VICTRELIS.xml:S2:2926:13	O
alfa	VICTRELIS.xml:S2:2940:4	O
and	VICTRELIS.xml:S2:2945:3	O
VICTRELIS	VICTRELIS.xml:S2:2949:9	O
must	VICTRELIS.xml:S2:2959:4	O
also	VICTRELIS.xml:S2:2964:4	O
be	VICTRELIS.xml:S2:2969:2	O
discontinued	VICTRELIS.xml:S2:2972:12	O
[	VICTRELIS.xml:S2:2985:1	O
see	VICTRELIS.xml:S2:2986:3	O
Dosage	VICTRELIS.xml:S2:2991:6	O
and	VICTRELIS.xml:S2:2998:3	O
Administration	VICTRELIS.xml:S2:3002:14	O
(	VICTRELIS.xml:S2:3017:1	O
2.3	VICTRELIS.xml:S2:3018:3	O
)	VICTRELIS.xml:S2:3021:1	O
]	VICTRELIS.xml:S2:3024:1	O
.	VICTRELIS.xml:S2:3027:1	O

Refer	VICTRELIS.xml:S2:3033:5	O
to	VICTRELIS.xml:S2:3039:2	O
the	VICTRELIS.xml:S2:3042:3	O
prescribing	VICTRELIS.xml:S2:3046:11	O
information	VICTRELIS.xml:S2:3058:11	O
for	VICTRELIS.xml:S2:3070:3	O
ribavirin	VICTRELIS.xml:S2:3074:9	O
for	VICTRELIS.xml:S2:3084:3	O
additional	VICTRELIS.xml:S2:3088:10	O
information	VICTRELIS.xml:S2:3099:11	O
regarding	VICTRELIS.xml:S2:3111:9	O
dose	VICTRELIS.xml:S2:3121:4	O
reduction	VICTRELIS.xml:S2:3126:9	O
and	VICTRELIS.xml:S2:3136:3	O
or	VICTRELIS.xml:S2:3140:2	O
discontinuation	VICTRELIS.xml:S2:3143:15	O
.	VICTRELIS.xml:S2:3158:1	O

In	VICTRELIS.xml:S2:3164:2	O
clinical	VICTRELIS.xml:S2:3167:8	O
trials	VICTRELIS.xml:S2:3176:6	O
with	VICTRELIS.xml:S2:3183:4	O
VICTRELIS	VICTRELIS.xml:S2:3188:9	O
,	VICTRELIS.xml:S2:3197:1	O
the	VICTRELIS.xml:S2:3199:3	O
proportion	VICTRELIS.xml:S2:3203:10	O
of	VICTRELIS.xml:S2:3214:2	O
subjects	VICTRELIS.xml:S2:3217:8	O
who	VICTRELIS.xml:S2:3226:3	O
experienced	VICTRELIS.xml:S2:3230:11	O
hemoglobin	VICTRELIS.xml:S2:3242:10	B-AdverseReaction
values	VICTRELIS.xml:S2:3253:6	I-AdverseReaction
less	VICTRELIS.xml:S2:3260:4	I-AdverseReaction
than	VICTRELIS.xml:S2:3265:4	I-AdverseReaction
10	VICTRELIS.xml:S2:3270:2	I-AdverseReaction
g	VICTRELIS.xml:S2:3273:1	I-AdverseReaction
per	VICTRELIS.xml:S2:3275:3	I-AdverseReaction
dL	VICTRELIS.xml:S2:3279:2	I-AdverseReaction
and	VICTRELIS.xml:S2:3282:3	O
less	VICTRELIS.xml:S2:3286:4	I-AdverseReaction
than	VICTRELIS.xml:S2:3291:4	I-AdverseReaction
8.5	VICTRELIS.xml:S2:3296:3	I-AdverseReaction
g	VICTRELIS.xml:S2:3300:1	I-AdverseReaction
per	VICTRELIS.xml:S2:3302:3	I-AdverseReaction
dL	VICTRELIS.xml:S2:3306:2	I-AdverseReaction
was	VICTRELIS.xml:S2:3309:3	O
higher	VICTRELIS.xml:S2:3313:6	O
in	VICTRELIS.xml:S2:3320:2	O
subjects	VICTRELIS.xml:S2:3323:8	O
treated	VICTRELIS.xml:S2:3332:7	O
with	VICTRELIS.xml:S2:3340:4	O
the	VICTRELIS.xml:S2:3345:3	O
combination	VICTRELIS.xml:S2:3349:11	O
of	VICTRELIS.xml:S2:3361:2	O
VICTRELIS	VICTRELIS.xml:S2:3364:9	O
with	VICTRELIS.xml:S2:3374:4	O
PegIntron	VICTRELIS.xml:S2:3379:9	O
(	VICTRELIS.xml:S2:3390:1	O
r	VICTRELIS.xml:S2:3391:1	O
)	VICTRELIS.xml:S2:3392:1	O
REBETOL	VICTRELIS.xml:S2:3396:7	O
(	VICTRELIS.xml:S2:3405:1	O
r	VICTRELIS.xml:S2:3406:1	O
)	VICTRELIS.xml:S2:3407:1	O
than	VICTRELIS.xml:S2:3410:4	O
in	VICTRELIS.xml:S2:3415:2	O
those	VICTRELIS.xml:S2:3418:5	O
treated	VICTRELIS.xml:S2:3424:7	O
with	VICTRELIS.xml:S2:3432:4	O
PegIntron	VICTRELIS.xml:S2:3437:9	O
REBETOL	VICTRELIS.xml:S2:3447:7	O
alone	VICTRELIS.xml:S2:3455:5	O
(	VICTRELIS.xml:S2:3461:1	O
see	VICTRELIS.xml:S2:3462:3	O
Table	VICTRELIS.xml:S2:3467:5	O
4	VICTRELIS.xml:S2:3473:1	O
)	VICTRELIS.xml:S2:3476:1	O
.	VICTRELIS.xml:S2:3477:1	O

With	VICTRELIS.xml:S2:3479:4	O
the	VICTRELIS.xml:S2:3484:3	O
interventions	VICTRELIS.xml:S2:3488:13	O
used	VICTRELIS.xml:S2:3502:4	O
for	VICTRELIS.xml:S2:3507:3	O
anemia	VICTRELIS.xml:S2:3511:6	O
management	VICTRELIS.xml:S2:3518:10	O
in	VICTRELIS.xml:S2:3529:2	O
the	VICTRELIS.xml:S2:3532:3	O
clinical	VICTRELIS.xml:S2:3536:8	O
trials	VICTRELIS.xml:S2:3545:6	O
,	VICTRELIS.xml:S2:3551:1	O
the	VICTRELIS.xml:S2:3553:3	O
average	VICTRELIS.xml:S2:3557:7	O
additional	VICTRELIS.xml:S2:3565:10	O
decrease	VICTRELIS.xml:S2:3576:8	O
of	VICTRELIS.xml:S2:3585:2	O
hemoglobin	VICTRELIS.xml:S2:3588:10	O
was	VICTRELIS.xml:S2:3599:3	O
approximately	VICTRELIS.xml:S2:3603:13	O
1	VICTRELIS.xml:S2:3617:1	O
g	VICTRELIS.xml:S2:3619:1	O
per	VICTRELIS.xml:S2:3621:3	O
dL	VICTRELIS.xml:S2:3625:2	O
.	VICTRELIS.xml:S2:3627:1	O

In	VICTRELIS.xml:S2:3633:2	O
clinical	VICTRELIS.xml:S2:3636:8	O
trials	VICTRELIS.xml:S2:3645:6	O
,	VICTRELIS.xml:S2:3651:1	O
the	VICTRELIS.xml:S2:3653:3	O
median	VICTRELIS.xml:S2:3657:6	O
time	VICTRELIS.xml:S2:3664:4	O
to	VICTRELIS.xml:S2:3669:2	O
onset	VICTRELIS.xml:S2:3672:5	O
of	VICTRELIS.xml:S2:3678:2	O
hemoglobin	VICTRELIS.xml:S2:3681:10	B-AdverseReaction
less	VICTRELIS.xml:S2:3692:4	I-AdverseReaction
than	VICTRELIS.xml:S2:3697:4	I-AdverseReaction
10	VICTRELIS.xml:S2:3702:2	I-AdverseReaction
g	VICTRELIS.xml:S2:3705:1	I-AdverseReaction
per	VICTRELIS.xml:S2:3707:3	I-AdverseReaction
dL	VICTRELIS.xml:S2:3711:2	I-AdverseReaction
from	VICTRELIS.xml:S2:3714:4	O
the	VICTRELIS.xml:S2:3719:3	O
initiation	VICTRELIS.xml:S2:3723:10	O
of	VICTRELIS.xml:S2:3734:2	O
therapy	VICTRELIS.xml:S2:3737:7	O
was	VICTRELIS.xml:S2:3745:3	O
similar	VICTRELIS.xml:S2:3749:7	O
among	VICTRELIS.xml:S2:3757:5	O
subjects	VICTRELIS.xml:S2:3763:8	O
treated	VICTRELIS.xml:S2:3772:7	O
with	VICTRELIS.xml:S2:3780:4	O
the	VICTRELIS.xml:S2:3785:3	O
combination	VICTRELIS.xml:S2:3789:11	O
of	VICTRELIS.xml:S2:3801:2	O
VICTRELIS	VICTRELIS.xml:S2:3804:9	O
and	VICTRELIS.xml:S2:3814:3	O
PegIntron	VICTRELIS.xml:S2:3818:9	O
REBETOL	VICTRELIS.xml:S2:3828:7	O
(	VICTRELIS.xml:S2:3836:1	O
71	VICTRELIS.xml:S2:3837:2	O
days	VICTRELIS.xml:S2:3840:4	O
with	VICTRELIS.xml:S2:3845:4	O
a	VICTRELIS.xml:S2:3850:1	O
range	VICTRELIS.xml:S2:3852:5	O
of	VICTRELIS.xml:S2:3858:2	O
15	VICTRELIS.xml:S2:3861:2	O
-	VICTRELIS.xml:S2:3863:1	O
337	VICTRELIS.xml:S2:3864:3	O
days	VICTRELIS.xml:S2:3868:4	O
)	VICTRELIS.xml:S2:3872:1	O
,	VICTRELIS.xml:S2:3873:1	O
compared	VICTRELIS.xml:S2:3875:8	O
to	VICTRELIS.xml:S2:3884:2	O
those	VICTRELIS.xml:S2:3887:5	O
who	VICTRELIS.xml:S2:3893:3	O
received	VICTRELIS.xml:S2:3897:8	O
PegIntron	VICTRELIS.xml:S2:3906:9	O
REBETOL	VICTRELIS.xml:S2:3916:7	O
(	VICTRELIS.xml:S2:3924:1	O
71	VICTRELIS.xml:S2:3925:2	O
days	VICTRELIS.xml:S2:3928:4	O
with	VICTRELIS.xml:S2:3933:4	O
a	VICTRELIS.xml:S2:3938:1	O
range	VICTRELIS.xml:S2:3940:5	O
of	VICTRELIS.xml:S2:3946:2	O
8	VICTRELIS.xml:S2:3949:1	O
-	VICTRELIS.xml:S2:3950:1	O
337	VICTRELIS.xml:S2:3951:3	O
days	VICTRELIS.xml:S2:3955:4	O
)	VICTRELIS.xml:S2:3959:1	O
.	VICTRELIS.xml:S2:3960:1	O

Certain	VICTRELIS.xml:S2:3962:7	O
adverse	VICTRELIS.xml:S2:3970:7	O
reactions	VICTRELIS.xml:S2:3978:9	O
consistent	VICTRELIS.xml:S2:3988:10	O
with	VICTRELIS.xml:S2:3999:4	O
symptoms	VICTRELIS.xml:S2:4004:8	O
of	VICTRELIS.xml:S2:4013:2	O
anemia	VICTRELIS.xml:S2:4016:6	B-AdverseReaction
,	VICTRELIS.xml:S2:4022:1	O
such	VICTRELIS.xml:S2:4024:4	O
as	VICTRELIS.xml:S2:4029:2	O
dyspnea	VICTRELIS.xml:S2:4032:7	B-AdverseReaction
,	VICTRELIS.xml:S2:4039:1	O
exertional	VICTRELIS.xml:S2:4041:10	B-AdverseReaction
dyspnea	VICTRELIS.xml:S2:4052:7	I-AdverseReaction
,	VICTRELIS.xml:S2:4059:1	O
dizziness	VICTRELIS.xml:S2:4061:9	B-AdverseReaction
and	VICTRELIS.xml:S2:4071:3	O
syncope	VICTRELIS.xml:S2:4075:7	B-AdverseReaction
were	VICTRELIS.xml:S2:4083:4	O
reported	VICTRELIS.xml:S2:4088:8	O
more	VICTRELIS.xml:S2:4097:4	O
frequently	VICTRELIS.xml:S2:4102:10	O
in	VICTRELIS.xml:S2:4113:2	O
subjects	VICTRELIS.xml:S2:4116:8	O
who	VICTRELIS.xml:S2:4125:3	O
received	VICTRELIS.xml:S2:4129:8	O
the	VICTRELIS.xml:S2:4138:3	O
combination	VICTRELIS.xml:S2:4142:11	O
of	VICTRELIS.xml:S2:4154:2	O
VICTRELIS	VICTRELIS.xml:S2:4157:9	O
with	VICTRELIS.xml:S2:4167:4	O
PegIntron	VICTRELIS.xml:S2:4172:9	O
REBETOL	VICTRELIS.xml:S2:4182:7	O
than	VICTRELIS.xml:S2:4190:4	O
in	VICTRELIS.xml:S2:4195:2	O
those	VICTRELIS.xml:S2:4198:5	O
treated	VICTRELIS.xml:S2:4204:7	O
with	VICTRELIS.xml:S2:4212:4	O
PegIntron	VICTRELIS.xml:S2:4217:9	O
REBETOL	VICTRELIS.xml:S2:4227:7	O
alone	VICTRELIS.xml:S2:4235:5	O
[	VICTRELIS.xml:S2:4241:1	O
see	VICTRELIS.xml:S2:4242:3	O
Adverse	VICTRELIS.xml:S2:4247:7	O
Reactions	VICTRELIS.xml:S2:4255:9	O
(	VICTRELIS.xml:S2:4265:1	O
6.1	VICTRELIS.xml:S2:4266:3	O
)	VICTRELIS.xml:S2:4269:1	O
]	VICTRELIS.xml:S2:4272:1	O
.	VICTRELIS.xml:S2:4273:1	O

In	VICTRELIS.xml:S2:4281:2	O
clinical	VICTRELIS.xml:S2:4284:8	O
trials	VICTRELIS.xml:S2:4293:6	O
with	VICTRELIS.xml:S2:4300:4	O
VICTRELIS	VICTRELIS.xml:S2:4305:9	O
,	VICTRELIS.xml:S2:4314:1	O
dose	VICTRELIS.xml:S2:4316:4	O
modifications	VICTRELIS.xml:S2:4321:13	O
(	VICTRELIS.xml:S2:4335:1	O
generally	VICTRELIS.xml:S2:4336:9	O
of	VICTRELIS.xml:S2:4346:2	O
PegIntron	VICTRELIS.xml:S2:4349:9	O
REBETOL	VICTRELIS.xml:S2:4359:7	O
)	VICTRELIS.xml:S2:4366:1	O
due	VICTRELIS.xml:S2:4368:3	O
to	VICTRELIS.xml:S2:4372:2	O
anemia	VICTRELIS.xml:S2:4375:6	B-AdverseReaction
occurred	VICTRELIS.xml:S2:4382:8	O
twice	VICTRELIS.xml:S2:4391:5	O
as	VICTRELIS.xml:S2:4397:2	O
often	VICTRELIS.xml:S2:4400:5	O
in	VICTRELIS.xml:S2:4406:2	O
subjects	VICTRELIS.xml:S2:4409:8	O
treated	VICTRELIS.xml:S2:4418:7	O
with	VICTRELIS.xml:S2:4426:4	O
the	VICTRELIS.xml:S2:4431:3	O
combination	VICTRELIS.xml:S2:4435:11	O
of	VICTRELIS.xml:S2:4447:2	O
VICTRELIS	VICTRELIS.xml:S2:4450:9	O
with	VICTRELIS.xml:S2:4460:4	O
PegIntron	VICTRELIS.xml:S2:4465:9	O
REBETOL	VICTRELIS.xml:S2:4475:7	O
(	VICTRELIS.xml:S2:4483:1	O
26%	VICTRELIS.xml:S2:4484:3	O
)	VICTRELIS.xml:S2:4487:1	O
compared	VICTRELIS.xml:S2:4489:8	O
to	VICTRELIS.xml:S2:4498:2	O
PegIntron	VICTRELIS.xml:S2:4501:9	O
REBETOL	VICTRELIS.xml:S2:4511:7	O
(	VICTRELIS.xml:S2:4519:1	O
13%	VICTRELIS.xml:S2:4520:3	O
)	VICTRELIS.xml:S2:4523:1	O
.	VICTRELIS.xml:S2:4524:1	O

The	VICTRELIS.xml:S2:4526:3	O
proportion	VICTRELIS.xml:S2:4530:10	O
of	VICTRELIS.xml:S2:4541:2	O
subjects	VICTRELIS.xml:S2:4544:8	O
who	VICTRELIS.xml:S2:4553:3	O
discontinued	VICTRELIS.xml:S2:4557:12	O
study	VICTRELIS.xml:S2:4570:5	O
drug	VICTRELIS.xml:S2:4576:4	O
due	VICTRELIS.xml:S2:4581:3	O
to	VICTRELIS.xml:S2:4585:2	O
anemia	VICTRELIS.xml:S2:4588:6	B-AdverseReaction
was	VICTRELIS.xml:S2:4595:3	O
1%	VICTRELIS.xml:S2:4599:2	O
in	VICTRELIS.xml:S2:4602:2	O
subjects	VICTRELIS.xml:S2:4605:8	O
treated	VICTRELIS.xml:S2:4614:7	O
with	VICTRELIS.xml:S2:4622:4	O
the	VICTRELIS.xml:S2:4627:3	O
combination	VICTRELIS.xml:S2:4631:11	O
of	VICTRELIS.xml:S2:4643:2	O
VICTRELIS	VICTRELIS.xml:S2:4646:9	O
with	VICTRELIS.xml:S2:4656:4	O
PegIntron	VICTRELIS.xml:S2:4661:9	O
REBETOL	VICTRELIS.xml:S2:4671:7	O
and	VICTRELIS.xml:S2:4679:3	O
1%	VICTRELIS.xml:S2:4683:2	O
in	VICTRELIS.xml:S2:4686:2	O
subjects	VICTRELIS.xml:S2:4689:8	O
who	VICTRELIS.xml:S2:4698:3	O
received	VICTRELIS.xml:S2:4702:8	O
PegIntron	VICTRELIS.xml:S2:4711:9	O
REBETOL	VICTRELIS.xml:S2:4721:7	O
.	VICTRELIS.xml:S2:4728:1	O

The	VICTRELIS.xml:S2:4730:3	O
use	VICTRELIS.xml:S2:4734:3	O
of	VICTRELIS.xml:S2:4738:2	O
erythropoiesis	VICTRELIS.xml:S2:4741:14	O
stimulating	VICTRELIS.xml:S2:4756:11	O
agents	VICTRELIS.xml:S2:4768:6	O
(	VICTRELIS.xml:S2:4775:1	O
ESAs	VICTRELIS.xml:S2:4776:4	O
)	VICTRELIS.xml:S2:4780:1	O
was	VICTRELIS.xml:S2:4782:3	O
permitted	VICTRELIS.xml:S2:4786:9	O
for	VICTRELIS.xml:S2:4796:3	O
management	VICTRELIS.xml:S2:4800:10	O
of	VICTRELIS.xml:S2:4811:2	O
anemia	VICTRELIS.xml:S2:4814:6	O
,	VICTRELIS.xml:S2:4820:1	O
at	VICTRELIS.xml:S2:4822:2	O
the	VICTRELIS.xml:S2:4825:3	O
investigator	VICTRELIS.xml:S2:4829:12	O
's	VICTRELIS.xml:S2:4841:2	O
discretion	VICTRELIS.xml:S2:4844:10	O
,	VICTRELIS.xml:S2:4854:1	O
with	VICTRELIS.xml:S2:4856:4	O
or	VICTRELIS.xml:S2:4861:2	O
without	VICTRELIS.xml:S2:4864:7	O
ribavirin	VICTRELIS.xml:S2:4872:9	O
dose	VICTRELIS.xml:S2:4882:4	O
reduction	VICTRELIS.xml:S2:4887:9	O
in	VICTRELIS.xml:S2:4897:2	O
the	VICTRELIS.xml:S2:4900:3	O
Phase	VICTRELIS.xml:S2:4904:5	O
2	VICTRELIS.xml:S2:4910:1	O
and	VICTRELIS.xml:S2:4912:3	O
3	VICTRELIS.xml:S2:4916:1	O
clinical	VICTRELIS.xml:S2:4918:8	O
trials	VICTRELIS.xml:S2:4927:6	O
.	VICTRELIS.xml:S2:4933:1	O

The	VICTRELIS.xml:S2:4935:3	O
proportion	VICTRELIS.xml:S2:4939:10	O
of	VICTRELIS.xml:S2:4950:2	O
subjects	VICTRELIS.xml:S2:4953:8	O
who	VICTRELIS.xml:S2:4962:3	O
received	VICTRELIS.xml:S2:4966:8	O
an	VICTRELIS.xml:S2:4975:2	O
ESA	VICTRELIS.xml:S2:4978:3	O
was	VICTRELIS.xml:S2:4982:3	O
43%	VICTRELIS.xml:S2:4986:3	O
in	VICTRELIS.xml:S2:4990:2	O
those	VICTRELIS.xml:S2:4993:5	O
treated	VICTRELIS.xml:S2:4999:7	O
with	VICTRELIS.xml:S2:5007:4	O
the	VICTRELIS.xml:S2:5012:3	O
combination	VICTRELIS.xml:S2:5016:11	O
of	VICTRELIS.xml:S2:5028:2	O
VICTRELIS	VICTRELIS.xml:S2:5031:9	O
with	VICTRELIS.xml:S2:5041:4	O
PegIntron	VICTRELIS.xml:S2:5046:9	O
REBETOL	VICTRELIS.xml:S2:5056:7	O
compared	VICTRELIS.xml:S2:5064:8	O
to	VICTRELIS.xml:S2:5073:2	O
24%	VICTRELIS.xml:S2:5076:3	O
in	VICTRELIS.xml:S2:5080:2	O
those	VICTRELIS.xml:S2:5083:5	O
treated	VICTRELIS.xml:S2:5089:7	O
with	VICTRELIS.xml:S2:5097:4	O
PegIntron	VICTRELIS.xml:S2:5102:9	O
REBETOL	VICTRELIS.xml:S2:5112:7	O
alone	VICTRELIS.xml:S2:5120:5	O
.	VICTRELIS.xml:S2:5125:1	O

The	VICTRELIS.xml:S2:5127:3	O
proportion	VICTRELIS.xml:S2:5131:10	O
of	VICTRELIS.xml:S2:5142:2	O
subjects	VICTRELIS.xml:S2:5145:8	O
who	VICTRELIS.xml:S2:5154:3	O
received	VICTRELIS.xml:S2:5158:8	O
a	VICTRELIS.xml:S2:5167:1	O
transfusion	VICTRELIS.xml:S2:5169:11	O
for	VICTRELIS.xml:S2:5181:3	O
the	VICTRELIS.xml:S2:5185:3	O
management	VICTRELIS.xml:S2:5189:10	O
of	VICTRELIS.xml:S2:5200:2	O
anemia	VICTRELIS.xml:S2:5203:6	O
was	VICTRELIS.xml:S2:5210:3	O
3%	VICTRELIS.xml:S2:5214:2	O
of	VICTRELIS.xml:S2:5217:2	O
subjects	VICTRELIS.xml:S2:5220:8	O
treated	VICTRELIS.xml:S2:5229:7	O
with	VICTRELIS.xml:S2:5237:4	O
the	VICTRELIS.xml:S2:5242:3	O
combination	VICTRELIS.xml:S2:5246:11	O
of	VICTRELIS.xml:S2:5258:2	O
VICTRELIS	VICTRELIS.xml:S2:5261:9	O
with	VICTRELIS.xml:S2:5271:4	O
PegIntron	VICTRELIS.xml:S2:5276:9	O
REBETOL	VICTRELIS.xml:S2:5286:7	O
compared	VICTRELIS.xml:S2:5294:8	O
to	VICTRELIS.xml:S2:5303:2	O
less	VICTRELIS.xml:S2:5306:4	O
than	VICTRELIS.xml:S2:5311:4	O
1%	VICTRELIS.xml:S2:5316:2	O
in	VICTRELIS.xml:S2:5319:2	O
subjects	VICTRELIS.xml:S2:5322:8	O
who	VICTRELIS.xml:S2:5331:3	O
received	VICTRELIS.xml:S2:5335:8	O
PegIntron	VICTRELIS.xml:S2:5344:9	O
REBETOL	VICTRELIS.xml:S2:5354:7	O
alone	VICTRELIS.xml:S2:5362:5	O
.	VICTRELIS.xml:S2:5367:1	O

Thromboembolic	VICTRELIS.xml:S2:5373:14	O
events	VICTRELIS.xml:S2:5388:6	O
have	VICTRELIS.xml:S2:5395:4	O
been	VICTRELIS.xml:S2:5400:4	O
associated	VICTRELIS.xml:S2:5405:10	O
with	VICTRELIS.xml:S2:5416:4	O
ESA	VICTRELIS.xml:S2:5421:3	O
use	VICTRELIS.xml:S2:5425:3	O
in	VICTRELIS.xml:S2:5429:2	O
other	VICTRELIS.xml:S2:5432:5	O
disease	VICTRELIS.xml:S2:5438:7	O
states	VICTRELIS.xml:S2:5446:6	O
;	VICTRELIS.xml:S2:5452:1	O
and	VICTRELIS.xml:S2:5454:3	O
have	VICTRELIS.xml:S2:5458:4	O
also	VICTRELIS.xml:S2:5463:4	O
been	VICTRELIS.xml:S2:5468:4	O
reported	VICTRELIS.xml:S2:5473:8	O
with	VICTRELIS.xml:S2:5482:4	O
peginterferon	VICTRELIS.xml:S2:5487:13	O
alfa	VICTRELIS.xml:S2:5501:4	O
use	VICTRELIS.xml:S2:5506:3	O
in	VICTRELIS.xml:S2:5510:2	O
hepatitis	VICTRELIS.xml:S2:5513:9	O
C	VICTRELIS.xml:S2:5523:1	O
patients	VICTRELIS.xml:S2:5525:8	O
.	VICTRELIS.xml:S2:5533:1	O

Thromboembolic	VICTRELIS.xml:S2:5535:14	B-AdverseReaction
events	VICTRELIS.xml:S2:5550:6	I-AdverseReaction
were	VICTRELIS.xml:S2:5557:4	O
reported	VICTRELIS.xml:S2:5562:8	O
in	VICTRELIS.xml:S2:5571:2	O
clinical	VICTRELIS.xml:S2:5574:8	O
trials	VICTRELIS.xml:S2:5583:6	O
with	VICTRELIS.xml:S2:5590:4	O
VICTRELIS	VICTRELIS.xml:S2:5595:9	O
among	VICTRELIS.xml:S2:5605:5	O
subjects	VICTRELIS.xml:S2:5611:8	O
receiving	VICTRELIS.xml:S2:5620:9	O
the	VICTRELIS.xml:S2:5630:3	O
combination	VICTRELIS.xml:S2:5634:11	O
of	VICTRELIS.xml:S2:5646:2	O
VICTRELIS	VICTRELIS.xml:S2:5649:9	O
with	VICTRELIS.xml:S2:5659:4	O
PegIntron	VICTRELIS.xml:S2:5664:9	O
REBETOL	VICTRELIS.xml:S2:5674:7	O
,	VICTRELIS.xml:S2:5681:1	O
and	VICTRELIS.xml:S2:5683:3	O
among	VICTRELIS.xml:S2:5687:5	O
those	VICTRELIS.xml:S2:5693:5	O
receiving	VICTRELIS.xml:S2:5699:9	O
PegIntron	VICTRELIS.xml:S2:5709:9	O
REBETOL	VICTRELIS.xml:S2:5719:7	O
alone	VICTRELIS.xml:S2:5727:5	O
,	VICTRELIS.xml:S2:5732:1	O
regardless	VICTRELIS.xml:S2:5734:10	O
of	VICTRELIS.xml:S2:5745:2	O
ESA	VICTRELIS.xml:S2:5748:3	O
use	VICTRELIS.xml:S2:5752:3	O
.	VICTRELIS.xml:S2:5755:1	O

No	VICTRELIS.xml:S2:5757:2	O
definite	VICTRELIS.xml:S2:5760:8	O
causality	VICTRELIS.xml:S2:5769:9	O
assessment	VICTRELIS.xml:S2:5779:10	O
or	VICTRELIS.xml:S2:5790:2	O
benefit	VICTRELIS.xml:S2:5793:7	O
risk	VICTRELIS.xml:S2:5801:4	O
assessment	VICTRELIS.xml:S2:5806:10	O
could	VICTRELIS.xml:S2:5817:5	O
be	VICTRELIS.xml:S2:5823:2	O
made	VICTRELIS.xml:S2:5826:4	O
for	VICTRELIS.xml:S2:5831:3	O
these	VICTRELIS.xml:S2:5835:5	O
events	VICTRELIS.xml:S2:5841:6	O
due	VICTRELIS.xml:S2:5848:3	O
to	VICTRELIS.xml:S2:5852:2	O
the	VICTRELIS.xml:S2:5855:3	O
presence	VICTRELIS.xml:S2:5859:8	O
of	VICTRELIS.xml:S2:5868:2	O
confounding	VICTRELIS.xml:S2:5871:11	O
factors	VICTRELIS.xml:S2:5883:7	O
and	VICTRELIS.xml:S2:5891:3	O
lack	VICTRELIS.xml:S2:5895:4	O
of	VICTRELIS.xml:S2:5900:2	O
randomization	VICTRELIS.xml:S2:5903:13	O
of	VICTRELIS.xml:S2:5917:2	O
ESA	VICTRELIS.xml:S2:5920:3	O
use	VICTRELIS.xml:S2:5924:3	O
.	VICTRELIS.xml:S2:5927:1	O

A	VICTRELIS.xml:S2:5933:1	O
randomized	VICTRELIS.xml:S2:5935:10	O
,	VICTRELIS.xml:S2:5945:1	O
parallel	VICTRELIS.xml:S2:5947:8	O
-	VICTRELIS.xml:S2:5955:1	O
arm	VICTRELIS.xml:S2:5956:3	O
,	VICTRELIS.xml:S2:5959:1	O
open	VICTRELIS.xml:S2:5961:4	O
-	VICTRELIS.xml:S2:5965:1	O
label	VICTRELIS.xml:S2:5966:5	O
clinical	VICTRELIS.xml:S2:5972:8	O
trial	VICTRELIS.xml:S2:5981:5	O
was	VICTRELIS.xml:S2:5987:3	O
conducted	VICTRELIS.xml:S2:5991:9	O
in	VICTRELIS.xml:S2:6001:2	O
previously	VICTRELIS.xml:S2:6004:10	O
untreated	VICTRELIS.xml:S2:6015:9	O
CHC	VICTRELIS.xml:S2:6025:3	O
subjects	VICTRELIS.xml:S2:6029:8	O
with	VICTRELIS.xml:S2:6038:4	O
genotype	VICTRELIS.xml:S2:6043:8	O
1	VICTRELIS.xml:S2:6052:1	O
infection	VICTRELIS.xml:S2:6054:9	O
to	VICTRELIS.xml:S2:6064:2	O
compare	VICTRELIS.xml:S2:6067:7	O
use	VICTRELIS.xml:S2:6075:3	O
of	VICTRELIS.xml:S2:6079:2	O
an	VICTRELIS.xml:S2:6082:2	O
ESA	VICTRELIS.xml:S2:6085:3	O
versus	VICTRELIS.xml:S2:6089:6	O
ribavirin	VICTRELIS.xml:S2:6096:9	O
dose	VICTRELIS.xml:S2:6106:4	O
reduction	VICTRELIS.xml:S2:6111:9	O
for	VICTRELIS.xml:S2:6121:3	O
initial	VICTRELIS.xml:S2:6125:7	O
management	VICTRELIS.xml:S2:6133:10	O
of	VICTRELIS.xml:S2:6144:2	O
anemia	VICTRELIS.xml:S2:6147:6	O
during	VICTRELIS.xml:S2:6154:6	O
therapy	VICTRELIS.xml:S2:6161:7	O
with	VICTRELIS.xml:S2:6169:4	O
VICTRELIS	VICTRELIS.xml:S2:6174:9	O
in	VICTRELIS.xml:S2:6184:2	O
combination	VICTRELIS.xml:S2:6187:11	O
with	VICTRELIS.xml:S2:6199:4	O
peginterferon	VICTRELIS.xml:S2:6204:13	O
alfa	VICTRELIS.xml:S2:6218:4	O
-	VICTRELIS.xml:S2:6222:1	O
2	VICTRELIS.xml:S2:6223:1	O
b	VICTRELIS.xml:S2:6224:1	O
and	VICTRELIS.xml:S2:6226:3	O
ribavirin	VICTRELIS.xml:S2:6230:9	O
.	VICTRELIS.xml:S2:6239:1	O

Similar	VICTRELIS.xml:S2:6241:7	O
SVR	VICTRELIS.xml:S2:6249:3	O
rates	VICTRELIS.xml:S2:6253:5	O
were	VICTRELIS.xml:S2:6259:4	O
reported	VICTRELIS.xml:S2:6264:8	O
in	VICTRELIS.xml:S2:6273:2	O
subjects	VICTRELIS.xml:S2:6276:8	O
who	VICTRELIS.xml:S2:6285:3	O
were	VICTRELIS.xml:S2:6289:4	O
randomized	VICTRELIS.xml:S2:6294:10	O
to	VICTRELIS.xml:S2:6305:2	O
receive	VICTRELIS.xml:S2:6308:7	O
ribavirin	VICTRELIS.xml:S2:6316:9	O
dose	VICTRELIS.xml:S2:6326:4	O
reduction	VICTRELIS.xml:S2:6331:9	O
compared	VICTRELIS.xml:S2:6341:8	O
to	VICTRELIS.xml:S2:6350:2	O
subjects	VICTRELIS.xml:S2:6353:8	O
who	VICTRELIS.xml:S2:6362:3	O
were	VICTRELIS.xml:S2:6366:4	O
randomized	VICTRELIS.xml:S2:6371:10	O
to	VICTRELIS.xml:S2:6382:2	O
receive	VICTRELIS.xml:S2:6385:7	O
an	VICTRELIS.xml:S2:6393:2	O
ESA	VICTRELIS.xml:S2:6396:3	O
.	VICTRELIS.xml:S2:6399:1	O

In	VICTRELIS.xml:S2:6401:2	O
this	VICTRELIS.xml:S2:6404:4	O
trial	VICTRELIS.xml:S2:6409:5	O
,	VICTRELIS.xml:S2:6414:1	O
use	VICTRELIS.xml:S2:6416:3	O
of	VICTRELIS.xml:S2:6420:2	O
ESAs	VICTRELIS.xml:S2:6423:4	O
was	VICTRELIS.xml:S2:6428:3	O
associated	VICTRELIS.xml:S2:6432:10	O
with	VICTRELIS.xml:S2:6443:4	O
an	VICTRELIS.xml:S2:6448:2	O
increased	VICTRELIS.xml:S2:6451:9	O
risk	VICTRELIS.xml:S2:6461:4	O
of	VICTRELIS.xml:S2:6466:2	O
thromboembolic	VICTRELIS.xml:S2:6469:14	O
events	VICTRELIS.xml:S2:6484:6	O
including	VICTRELIS.xml:S2:6491:9	O
pulmonary	VICTRELIS.xml:S2:6501:9	O
embolism	VICTRELIS.xml:S2:6511:8	O
,	VICTRELIS.xml:S2:6519:1	O
acute	VICTRELIS.xml:S2:6521:5	O
myocardial	VICTRELIS.xml:S2:6527:10	O
infarction	VICTRELIS.xml:S2:6538:10	O
,	VICTRELIS.xml:S2:6548:1	O
cerebrovascular	VICTRELIS.xml:S2:6550:15	O
accident	VICTRELIS.xml:S2:6566:8	O
,	VICTRELIS.xml:S2:6574:1	O
and	VICTRELIS.xml:S2:6576:3	O
deep	VICTRELIS.xml:S2:6580:4	O
vein	VICTRELIS.xml:S2:6585:4	O
thrombosis	VICTRELIS.xml:S2:6590:10	O
compared	VICTRELIS.xml:S2:6601:8	O
to	VICTRELIS.xml:S2:6610:2	O
ribavirin	VICTRELIS.xml:S2:6613:9	O
dose	VICTRELIS.xml:S2:6623:4	O
reduction	VICTRELIS.xml:S2:6628:9	O
alone	VICTRELIS.xml:S2:6638:5	O
.	VICTRELIS.xml:S2:6643:1	O

The	VICTRELIS.xml:S2:6645:3	O
treatment	VICTRELIS.xml:S2:6649:9	O
discontinuation	VICTRELIS.xml:S2:6659:15	O
rate	VICTRELIS.xml:S2:6675:4	O
due	VICTRELIS.xml:S2:6680:3	O
to	VICTRELIS.xml:S2:6684:2	O
anemia	VICTRELIS.xml:S2:6687:6	B-AdverseReaction
was	VICTRELIS.xml:S2:6694:3	O
similar	VICTRELIS.xml:S2:6698:7	O
in	VICTRELIS.xml:S2:6706:2	O
subjects	VICTRELIS.xml:S2:6709:8	O
randomized	VICTRELIS.xml:S2:6718:10	O
to	VICTRELIS.xml:S2:6729:2	O
receive	VICTRELIS.xml:S2:6732:7	O
ribavirin	VICTRELIS.xml:S2:6740:9	O
dose	VICTRELIS.xml:S2:6750:4	O
reduction	VICTRELIS.xml:S2:6755:9	O
compared	VICTRELIS.xml:S2:6765:8	O
to	VICTRELIS.xml:S2:6774:2	O
subjects	VICTRELIS.xml:S2:6777:8	O
randomized	VICTRELIS.xml:S2:6786:10	O
to	VICTRELIS.xml:S2:6797:2	O
receive	VICTRELIS.xml:S2:6800:7	O
ESA	VICTRELIS.xml:S2:6808:3	O
(	VICTRELIS.xml:S2:6812:1	O
2%	VICTRELIS.xml:S2:6813:2	O
in	VICTRELIS.xml:S2:6816:2	O
each	VICTRELIS.xml:S2:6819:4	O
group	VICTRELIS.xml:S2:6824:5	O
)	VICTRELIS.xml:S2:6829:1	O
.	VICTRELIS.xml:S2:6830:1	O

The	VICTRELIS.xml:S2:6832:3	O
transfusion	VICTRELIS.xml:S2:6836:11	O
rate	VICTRELIS.xml:S2:6848:4	O
was	VICTRELIS.xml:S2:6853:3	O
4%	VICTRELIS.xml:S2:6857:2	O
in	VICTRELIS.xml:S2:6860:2	O
subjects	VICTRELIS.xml:S2:6863:8	O
randomized	VICTRELIS.xml:S2:6872:10	O
to	VICTRELIS.xml:S2:6883:2	O
receive	VICTRELIS.xml:S2:6886:7	O
ribavirin	VICTRELIS.xml:S2:6894:9	O
dose	VICTRELIS.xml:S2:6904:4	O
reduction	VICTRELIS.xml:S2:6909:9	O
and	VICTRELIS.xml:S2:6919:3	O
2%	VICTRELIS.xml:S2:6923:2	O
in	VICTRELIS.xml:S2:6926:2	O
subjects	VICTRELIS.xml:S2:6929:8	O
randomized	VICTRELIS.xml:S2:6938:10	O
to	VICTRELIS.xml:S2:6949:2	O
receive	VICTRELIS.xml:S2:6952:7	O
ESA	VICTRELIS.xml:S2:6960:3	O
.	VICTRELIS.xml:S2:6963:1	O

Ribavirin	VICTRELIS.xml:S2:6969:9	O
dose	VICTRELIS.xml:S2:6979:4	O
reduction	VICTRELIS.xml:S2:6984:9	O
is	VICTRELIS.xml:S2:6994:2	O
recommended	VICTRELIS.xml:S2:6997:11	O
for	VICTRELIS.xml:S2:7009:3	O
the	VICTRELIS.xml:S2:7013:3	O
initial	VICTRELIS.xml:S2:7017:7	O
management	VICTRELIS.xml:S2:7025:10	O
of	VICTRELIS.xml:S2:7036:2	O
anemia	VICTRELIS.xml:S2:7039:6	O
.	VICTRELIS.xml:S2:7045:1	O

5.3	VICTRELIS.xml:S2:7054:3	O
Neutropenia	VICTRELIS.xml:S2:7058:11	O
(	VICTRELIS.xml:S2:7070:1	O
Use	VICTRELIS.xml:S2:7071:3	O
with	VICTRELIS.xml:S2:7075:4	O
Ribavirin	VICTRELIS.xml:S2:7080:9	O
and	VICTRELIS.xml:S2:7090:3	O
Peginterferon	VICTRELIS.xml:S2:7094:13	O
Alfa	VICTRELIS.xml:S2:7108:4	O
)	VICTRELIS.xml:S2:7112:1	O

In	VICTRELIS.xml:S2:7119:2	O
Phase	VICTRELIS.xml:S2:7122:5	O
2	VICTRELIS.xml:S2:7128:1	O
and	VICTRELIS.xml:S2:7130:3	O
3	VICTRELIS.xml:S2:7134:1	O
clinical	VICTRELIS.xml:S2:7136:8	O
trials	VICTRELIS.xml:S2:7145:6	O
,	VICTRELIS.xml:S2:7151:1	O
seven	VICTRELIS.xml:S2:7153:5	O
percent	VICTRELIS.xml:S2:7159:7	O
of	VICTRELIS.xml:S2:7167:2	O
subjects	VICTRELIS.xml:S2:7170:8	O
receiving	VICTRELIS.xml:S2:7179:9	O
the	VICTRELIS.xml:S2:7189:3	O
combination	VICTRELIS.xml:S2:7193:11	O
of	VICTRELIS.xml:S2:7205:2	O
VICTRELIS	VICTRELIS.xml:S2:7208:9	O
with	VICTRELIS.xml:S2:7218:4	O
PegIntron	VICTRELIS.xml:S2:7223:9	O
REBETOL	VICTRELIS.xml:S2:7233:7	O
had	VICTRELIS.xml:S2:7241:3	O
neutrophil	VICTRELIS.xml:S2:7245:10	B-AdverseReaction
counts	VICTRELIS.xml:S2:7256:6	I-AdverseReaction
of	VICTRELIS.xml:S2:7263:2	I-AdverseReaction
less	VICTRELIS.xml:S2:7266:4	I-AdverseReaction
than	VICTRELIS.xml:S2:7271:4	I-AdverseReaction
0.5	VICTRELIS.xml:S2:7276:3	I-AdverseReaction
10	VICTRELIS.xml:S2:7282:2	I-AdverseReaction
9	VICTRELIS.xml:S2:7286:1	I-AdverseReaction
per	VICTRELIS.xml:S2:7289:3	I-AdverseReaction
L	VICTRELIS.xml:S2:7293:1	I-AdverseReaction
compared	VICTRELIS.xml:S2:7295:8	O
to	VICTRELIS.xml:S2:7304:2	O
4%	VICTRELIS.xml:S2:7307:2	O
of	VICTRELIS.xml:S2:7310:2	O
subjects	VICTRELIS.xml:S2:7313:8	O
receiving	VICTRELIS.xml:S2:7322:9	O
PegIntron	VICTRELIS.xml:S2:7332:9	O
REBETOL	VICTRELIS.xml:S2:7342:7	O
alone	VICTRELIS.xml:S2:7350:5	O
(	VICTRELIS.xml:S2:7356:1	O
see	VICTRELIS.xml:S2:7357:3	O
Table	VICTRELIS.xml:S2:7362:5	O
4	VICTRELIS.xml:S2:7368:1	O
)	VICTRELIS.xml:S2:7371:1	O
.	VICTRELIS.xml:S2:7372:1	O

Three	VICTRELIS.xml:S2:7374:5	O
subjects	VICTRELIS.xml:S2:7380:8	O
experienced	VICTRELIS.xml:S2:7389:11	O
severe	VICTRELIS.xml:S2:7401:6	B-Severity
or	VICTRELIS.xml:S2:7408:2	O
life	VICTRELIS.xml:S2:7411:4	B-Severity
-	VICTRELIS.xml:S2:7415:1	I-Severity
threatening	VICTRELIS.xml:S2:7416:11	I-Severity
infections	VICTRELIS.xml:S2:7428:10	B-AdverseReaction
associated	VICTRELIS.xml:S2:7439:10	O
with	VICTRELIS.xml:S2:7450:4	O
neutropenia	VICTRELIS.xml:S2:7455:11	B-AdverseReaction
,	VICTRELIS.xml:S2:7466:1	O
and	VICTRELIS.xml:S2:7468:3	O
two	VICTRELIS.xml:S2:7472:3	O
subjects	VICTRELIS.xml:S2:7476:8	O
experienced	VICTRELIS.xml:S2:7485:11	O
life	VICTRELIS.xml:S2:7497:4	B-Severity
-	VICTRELIS.xml:S2:7501:1	I-Severity
threatening	VICTRELIS.xml:S2:7502:11	I-Severity
neutropenia	VICTRELIS.xml:S2:7514:11	B-AdverseReaction
while	VICTRELIS.xml:S2:7526:5	O
receiving	VICTRELIS.xml:S2:7532:9	O
the	VICTRELIS.xml:S2:7542:3	O
combination	VICTRELIS.xml:S2:7546:11	O
of	VICTRELIS.xml:S2:7558:2	O
VICTRELIS	VICTRELIS.xml:S2:7561:9	O
with	VICTRELIS.xml:S2:7571:4	O
PegIntron	VICTRELIS.xml:S2:7576:9	O
REBETOL	VICTRELIS.xml:S2:7586:7	O
.	VICTRELIS.xml:S2:7593:1	O

Complete	VICTRELIS.xml:S2:7595:8	O
blood	VICTRELIS.xml:S2:7604:5	O
counts	VICTRELIS.xml:S2:7610:6	O
(	VICTRELIS.xml:S2:7617:1	O
with	VICTRELIS.xml:S2:7618:4	O
white	VICTRELIS.xml:S2:7623:5	O
blood	VICTRELIS.xml:S2:7629:5	O
cell	VICTRELIS.xml:S2:7635:4	O
differential	VICTRELIS.xml:S2:7640:12	O
counts	VICTRELIS.xml:S2:7653:6	O
)	VICTRELIS.xml:S2:7659:1	O
should	VICTRELIS.xml:S2:7661:6	O
be	VICTRELIS.xml:S2:7668:2	O
obtained	VICTRELIS.xml:S2:7671:8	O
at	VICTRELIS.xml:S2:7680:2	O
pretreatment	VICTRELIS.xml:S2:7683:12	O
,	VICTRELIS.xml:S2:7695:1	O
and	VICTRELIS.xml:S2:7697:3	O
at	VICTRELIS.xml:S2:7701:2	O
Treatment	VICTRELIS.xml:S2:7704:9	O
Weeks	VICTRELIS.xml:S2:7714:5	O
2	VICTRELIS.xml:S2:7720:1	O
,	VICTRELIS.xml:S2:7721:1	O
4	VICTRELIS.xml:S2:7723:1	O
,	VICTRELIS.xml:S2:7724:1	O
8	VICTRELIS.xml:S2:7726:1	O
,	VICTRELIS.xml:S2:7727:1	O
and	VICTRELIS.xml:S2:7729:3	O
12	VICTRELIS.xml:S2:7733:2	O
,	VICTRELIS.xml:S2:7735:1	O
and	VICTRELIS.xml:S2:7737:3	O
should	VICTRELIS.xml:S2:7741:6	O
be	VICTRELIS.xml:S2:7748:2	O
monitored	VICTRELIS.xml:S2:7751:9	O
closely	VICTRELIS.xml:S2:7761:7	O
at	VICTRELIS.xml:S2:7769:2	O
other	VICTRELIS.xml:S2:7772:5	O
time	VICTRELIS.xml:S2:7778:4	O
points	VICTRELIS.xml:S2:7783:6	O
,	VICTRELIS.xml:S2:7789:1	O
as	VICTRELIS.xml:S2:7791:2	O
clinically	VICTRELIS.xml:S2:7794:10	O
appropriate	VICTRELIS.xml:S2:7805:11	O
.	VICTRELIS.xml:S2:7816:1	O

Decreases	VICTRELIS.xml:S2:7818:9	O
in	VICTRELIS.xml:S2:7828:2	O
neutrophil	VICTRELIS.xml:S2:7831:10	O
counts	VICTRELIS.xml:S2:7842:6	O
may	VICTRELIS.xml:S2:7849:3	O
require	VICTRELIS.xml:S2:7853:7	O
dose	VICTRELIS.xml:S2:7861:4	O
reduction	VICTRELIS.xml:S2:7866:9	O
or	VICTRELIS.xml:S2:7876:2	O
discontinuation	VICTRELIS.xml:S2:7879:15	O
of	VICTRELIS.xml:S2:7895:2	O
peginterferon	VICTRELIS.xml:S2:7898:13	O
alfa	VICTRELIS.xml:S2:7912:4	O
and	VICTRELIS.xml:S2:7917:3	O
ribavirin	VICTRELIS.xml:S2:7921:9	O
.	VICTRELIS.xml:S2:7930:1	O

If	VICTRELIS.xml:S2:7932:2	O
peginterferon	VICTRELIS.xml:S2:7935:13	O
alfa	VICTRELIS.xml:S2:7949:4	O
and	VICTRELIS.xml:S2:7954:3	O
ribavirin	VICTRELIS.xml:S2:7958:9	O
are	VICTRELIS.xml:S2:7968:3	O
permanently	VICTRELIS.xml:S2:7972:11	O
discontinued	VICTRELIS.xml:S2:7984:12	O
,	VICTRELIS.xml:S2:7996:1	O
then	VICTRELIS.xml:S2:7998:4	O
VICTRELIS	VICTRELIS.xml:S2:8003:9	O
must	VICTRELIS.xml:S2:8013:4	O
also	VICTRELIS.xml:S2:8018:4	O
be	VICTRELIS.xml:S2:8023:2	O
discontinued	VICTRELIS.xml:S2:8026:12	O
[	VICTRELIS.xml:S2:8039:1	O
see	VICTRELIS.xml:S2:8040:3	O
Dosage	VICTRELIS.xml:S2:8045:6	O
and	VICTRELIS.xml:S2:8052:3	O
Administration	VICTRELIS.xml:S2:8056:14	O
(	VICTRELIS.xml:S2:8071:1	O
2.3	VICTRELIS.xml:S2:8072:3	O
)	VICTRELIS.xml:S2:8075:1	O
]	VICTRELIS.xml:S2:8078:1	O
.	VICTRELIS.xml:S2:8079:1	O

Refer	VICTRELIS.xml:S2:8087:5	O
to	VICTRELIS.xml:S2:8093:2	O
the	VICTRELIS.xml:S2:8096:3	O
prescribing	VICTRELIS.xml:S2:8100:11	O
information	VICTRELIS.xml:S2:8112:11	O
for	VICTRELIS.xml:S2:8124:3	O
peginterferon	VICTRELIS.xml:S2:8128:13	O
alfa	VICTRELIS.xml:S2:8142:4	O
and	VICTRELIS.xml:S2:8147:3	O
ribavirin	VICTRELIS.xml:S2:8151:9	O
for	VICTRELIS.xml:S2:8161:3	O
additional	VICTRELIS.xml:S2:8165:10	O
information	VICTRELIS.xml:S2:8176:11	O
regarding	VICTRELIS.xml:S2:8188:9	O
dose	VICTRELIS.xml:S2:8198:4	O
reduction	VICTRELIS.xml:S2:8203:9	O
or	VICTRELIS.xml:S2:8213:2	O
discontinuation	VICTRELIS.xml:S2:8216:15	O
.	VICTRELIS.xml:S2:8231:1	O

5.4	VICTRELIS.xml:S2:8240:3	O
Pancytopenia	VICTRELIS.xml:S2:8244:12	O
(	VICTRELIS.xml:S2:8257:1	O
Use	VICTRELIS.xml:S2:8258:3	O
with	VICTRELIS.xml:S2:8262:4	O
Ribavirin	VICTRELIS.xml:S2:8267:9	O
and	VICTRELIS.xml:S2:8277:3	O
Peginterferon	VICTRELIS.xml:S2:8281:13	O
Alfa	VICTRELIS.xml:S2:8295:4	O
)	VICTRELIS.xml:S2:8299:1	O

Serious	VICTRELIS.xml:S2:8307:7	B-Severity
cases	VICTRELIS.xml:S2:8315:5	O
of	VICTRELIS.xml:S2:8321:2	O
pancytopenia	VICTRELIS.xml:S2:8324:12	B-AdverseReaction
have	VICTRELIS.xml:S2:8337:4	O
been	VICTRELIS.xml:S2:8342:4	O
reported	VICTRELIS.xml:S2:8347:8	O
postmarketing	VICTRELIS.xml:S2:8356:13	O
in	VICTRELIS.xml:S2:8370:2	O
patients	VICTRELIS.xml:S2:8373:8	O
receiving	VICTRELIS.xml:S2:8382:9	O
VICTRELIS	VICTRELIS.xml:S2:8392:9	O
in	VICTRELIS.xml:S2:8402:2	O
combination	VICTRELIS.xml:S2:8405:11	O
with	VICTRELIS.xml:S2:8417:4	O
peginterferon	VICTRELIS.xml:S2:8422:13	O
alfa	VICTRELIS.xml:S2:8436:4	O
and	VICTRELIS.xml:S2:8441:3	O
ribavirin	VICTRELIS.xml:S2:8445:9	O
.	VICTRELIS.xml:S2:8454:1	O

Complete	VICTRELIS.xml:S2:8456:8	O
blood	VICTRELIS.xml:S2:8465:5	O
counts	VICTRELIS.xml:S2:8471:6	O
(	VICTRELIS.xml:S2:8478:1	O
with	VICTRELIS.xml:S2:8479:4	O
white	VICTRELIS.xml:S2:8484:5	O
blood	VICTRELIS.xml:S2:8490:5	O
cell	VICTRELIS.xml:S2:8496:4	O
differential	VICTRELIS.xml:S2:8501:12	O
counts	VICTRELIS.xml:S2:8514:6	O
)	VICTRELIS.xml:S2:8520:1	O
should	VICTRELIS.xml:S2:8522:6	O
be	VICTRELIS.xml:S2:8529:2	O
obtained	VICTRELIS.xml:S2:8532:8	O
at	VICTRELIS.xml:S2:8541:2	O
pretreatment	VICTRELIS.xml:S2:8544:12	O
,	VICTRELIS.xml:S2:8556:1	O
and	VICTRELIS.xml:S2:8558:3	O
at	VICTRELIS.xml:S2:8562:2	O
Treatment	VICTRELIS.xml:S2:8565:9	O
Weeks	VICTRELIS.xml:S2:8575:5	O
2	VICTRELIS.xml:S2:8581:1	O
,	VICTRELIS.xml:S2:8582:1	O
4	VICTRELIS.xml:S2:8584:1	O
,	VICTRELIS.xml:S2:8585:1	O
8	VICTRELIS.xml:S2:8587:1	O
,	VICTRELIS.xml:S2:8588:1	O
and	VICTRELIS.xml:S2:8590:3	O
12	VICTRELIS.xml:S2:8594:2	O
,	VICTRELIS.xml:S2:8596:1	O
and	VICTRELIS.xml:S2:8598:3	O
should	VICTRELIS.xml:S2:8602:6	O
be	VICTRELIS.xml:S2:8609:2	O
monitored	VICTRELIS.xml:S2:8612:9	O
closely	VICTRELIS.xml:S2:8622:7	O
at	VICTRELIS.xml:S2:8630:2	O
other	VICTRELIS.xml:S2:8633:5	O
time	VICTRELIS.xml:S2:8639:4	O
points	VICTRELIS.xml:S2:8644:6	O
,	VICTRELIS.xml:S2:8650:1	O
as	VICTRELIS.xml:S2:8652:2	O
clinically	VICTRELIS.xml:S2:8655:10	O
appropriate	VICTRELIS.xml:S2:8666:11	O
.	VICTRELIS.xml:S2:8677:1	O

Refer	VICTRELIS.xml:S2:8686:5	O
to	VICTRELIS.xml:S2:8692:2	O
the	VICTRELIS.xml:S2:8695:3	O
prescribing	VICTRELIS.xml:S2:8699:11	O
information	VICTRELIS.xml:S2:8711:11	O
for	VICTRELIS.xml:S2:8723:3	O
ribavirin	VICTRELIS.xml:S2:8727:9	O
and	VICTRELIS.xml:S2:8737:3	O
peginterferon	VICTRELIS.xml:S2:8741:13	O
alfa	VICTRELIS.xml:S2:8755:4	O
for	VICTRELIS.xml:S2:8760:3	O
guidelines	VICTRELIS.xml:S2:8764:10	O
for	VICTRELIS.xml:S2:8775:3	O
discontinuation	VICTRELIS.xml:S2:8779:15	O
of	VICTRELIS.xml:S2:8795:2	O
therapy	VICTRELIS.xml:S2:8798:7	O
based	VICTRELIS.xml:S2:8806:5	O
on	VICTRELIS.xml:S2:8812:2	O
laboratory	VICTRELIS.xml:S2:8815:10	O
parameters	VICTRELIS.xml:S2:8826:10	O
.	VICTRELIS.xml:S2:8836:1	O

5.5	VICTRELIS.xml:S2:8847:3	O
Hypersensitivity	VICTRELIS.xml:S2:8851:16	O

Serious	VICTRELIS.xml:S2:8873:7	B-Severity
acute	VICTRELIS.xml:S2:8881:5	B-AdverseReaction
hypersensitivity	VICTRELIS.xml:S2:8887:16	I-AdverseReaction
reactions	VICTRELIS.xml:S2:8904:9	I-AdverseReaction
(	VICTRELIS.xml:S2:8914:1	O
e	VICTRELIS.xml:S2:8915:1	O
.	VICTRELIS.xml:S2:8916:1	O
g	VICTRELIS.xml:S2:8917:1	O
.	VICTRELIS.xml:S2:8918:1	O
,	VICTRELIS.xml:S2:8919:1	O
urticaria	VICTRELIS.xml:S2:8921:9	B-AdverseReaction
,	VICTRELIS.xml:S2:8930:1	O
angioedema	VICTRELIS.xml:S2:8932:10	B-AdverseReaction
)	VICTRELIS.xml:S2:8942:1	O
have	VICTRELIS.xml:S2:8944:4	O
been	VICTRELIS.xml:S2:8949:4	O
observed	VICTRELIS.xml:S2:8954:8	O
during	VICTRELIS.xml:S2:8963:6	O
combination	VICTRELIS.xml:S2:8970:11	O
therapy	VICTRELIS.xml:S2:8982:7	O
with	VICTRELIS.xml:S2:8990:4	O
VICTRELIS	VICTRELIS.xml:S2:8995:9	O
,	VICTRELIS.xml:S2:9004:1	O
peginterferon	VICTRELIS.xml:S2:9006:13	O
alfa	VICTRELIS.xml:S2:9020:4	O
and	VICTRELIS.xml:S2:9025:3	O
ribavirin	VICTRELIS.xml:S2:9029:9	O
.	VICTRELIS.xml:S2:9038:1	O

If	VICTRELIS.xml:S2:9040:2	O
such	VICTRELIS.xml:S2:9043:4	O
an	VICTRELIS.xml:S2:9048:2	O
acute	VICTRELIS.xml:S2:9051:5	O
reaction	VICTRELIS.xml:S2:9057:8	O
occurs	VICTRELIS.xml:S2:9066:6	O
,	VICTRELIS.xml:S2:9072:1	O
combination	VICTRELIS.xml:S2:9074:11	O
therapy	VICTRELIS.xml:S2:9086:7	O
should	VICTRELIS.xml:S2:9094:6	O
be	VICTRELIS.xml:S2:9101:2	O
discontinued	VICTRELIS.xml:S2:9104:12	O
and	VICTRELIS.xml:S2:9117:3	O
appropriate	VICTRELIS.xml:S2:9121:11	O
medical	VICTRELIS.xml:S2:9133:7	O
therapy	VICTRELIS.xml:S2:9141:7	O
immediately	VICTRELIS.xml:S2:9149:11	O
instituted	VICTRELIS.xml:S2:9161:10	O
[	VICTRELIS.xml:S2:9172:1	O
see	VICTRELIS.xml:S2:9173:3	O
Contraindications	VICTRELIS.xml:S2:9178:17	O
(	VICTRELIS.xml:S2:9196:1	O
4	VICTRELIS.xml:S2:9197:1	O
)	VICTRELIS.xml:S2:9198:1	O
and	VICTRELIS.xml:S2:9201:3	O
Adverse	VICTRELIS.xml:S2:9206:7	O
Reactions	VICTRELIS.xml:S2:9214:9	O
(	VICTRELIS.xml:S2:9224:1	O
6.2	VICTRELIS.xml:S2:9225:3	O
)	VICTRELIS.xml:S2:9228:1	O
]	VICTRELIS.xml:S2:9231:1	O
.	VICTRELIS.xml:S2:9234:1	O

5.6	VICTRELIS.xml:S2:9243:3	O
Drug	VICTRELIS.xml:S2:9247:4	O
Interactions	VICTRELIS.xml:S2:9252:12	O

See	VICTRELIS.xml:S2:9270:3	O
Table	VICTRELIS.xml:S2:9275:5	O
2	VICTRELIS.xml:S2:9281:1	O
for	VICTRELIS.xml:S2:9284:3	O
a	VICTRELIS.xml:S2:9288:1	O
listing	VICTRELIS.xml:S2:9290:7	O
of	VICTRELIS.xml:S2:9298:2	O
drugs	VICTRELIS.xml:S2:9301:5	O
that	VICTRELIS.xml:S2:9307:4	O
are	VICTRELIS.xml:S2:9312:3	O
contraindicated	VICTRELIS.xml:S2:9316:15	O
for	VICTRELIS.xml:S2:9332:3	O
use	VICTRELIS.xml:S2:9336:3	O
with	VICTRELIS.xml:S2:9340:4	O
VICTRELIS	VICTRELIS.xml:S2:9345:9	O
due	VICTRELIS.xml:S2:9355:3	O
to	VICTRELIS.xml:S2:9359:2	O
potentially	VICTRELIS.xml:S2:9362:11	O
life	VICTRELIS.xml:S2:9374:4	O
-	VICTRELIS.xml:S2:9378:1	O
threatening	VICTRELIS.xml:S2:9379:11	O
adverse	VICTRELIS.xml:S2:9391:7	O
events	VICTRELIS.xml:S2:9399:6	O
,	VICTRELIS.xml:S2:9405:1	O
significant	VICTRELIS.xml:S2:9407:11	O
drug	VICTRELIS.xml:S2:9419:4	O
interactions	VICTRELIS.xml:S2:9424:12	O
or	VICTRELIS.xml:S2:9437:2	O
loss	VICTRELIS.xml:S2:9440:4	O
of	VICTRELIS.xml:S2:9445:2	O
virologic	VICTRELIS.xml:S2:9448:9	O
activity	VICTRELIS.xml:S2:9458:8	O
[	VICTRELIS.xml:S2:9467:1	O
see	VICTRELIS.xml:S2:9468:3	O
Contraindications	VICTRELIS.xml:S2:9473:17	O
(	VICTRELIS.xml:S2:9491:1	O
4	VICTRELIS.xml:S2:9492:1	O
)	VICTRELIS.xml:S2:9493:1	O
]	VICTRELIS.xml:S2:9496:1	O
.	VICTRELIS.xml:S2:9497:1	O

Please	VICTRELIS.xml:S2:9500:6	O
refer	VICTRELIS.xml:S2:9507:5	O
to	VICTRELIS.xml:S2:9513:2	O
Table	VICTRELIS.xml:S2:9517:5	O
5	VICTRELIS.xml:S2:9523:1	O
for	VICTRELIS.xml:S2:9526:3	O
established	VICTRELIS.xml:S2:9530:11	O
and	VICTRELIS.xml:S2:9542:3	O
other	VICTRELIS.xml:S2:9546:5	O
potentially	VICTRELIS.xml:S2:9552:11	O
significant	VICTRELIS.xml:S2:9564:11	O
drug	VICTRELIS.xml:S2:9576:4	O
interactions	VICTRELIS.xml:S2:9581:12	O
[	VICTRELIS.xml:S2:9594:1	O
see	VICTRELIS.xml:S2:9595:3	O
Drug	VICTRELIS.xml:S2:9600:4	O
Interactions	VICTRELIS.xml:S2:9605:12	O
(	VICTRELIS.xml:S2:9618:1	O
7.3	VICTRELIS.xml:S2:9619:3	O
)	VICTRELIS.xml:S2:9622:1	O
]	VICTRELIS.xml:S2:9625:1	O
.	VICTRELIS.xml:S2:9626:1	O

5.7	VICTRELIS.xml:S2:9637:3	O
Laboratory	VICTRELIS.xml:S2:9641:10	O
Tests	VICTRELIS.xml:S2:9652:5	O

HCV	VICTRELIS.xml:S2:9663:3	O
-	VICTRELIS.xml:S2:9666:1	O
RNA	VICTRELIS.xml:S2:9667:3	O
levels	VICTRELIS.xml:S2:9671:6	O
should	VICTRELIS.xml:S2:9678:6	O
be	VICTRELIS.xml:S2:9685:2	O
monitored	VICTRELIS.xml:S2:9688:9	O
at	VICTRELIS.xml:S2:9698:2	O
Treatment	VICTRELIS.xml:S2:9701:9	O
Weeks	VICTRELIS.xml:S2:9711:5	O
4	VICTRELIS.xml:S2:9717:1	O
,	VICTRELIS.xml:S2:9718:1	O
8	VICTRELIS.xml:S2:9720:1	O
,	VICTRELIS.xml:S2:9721:1	O
12	VICTRELIS.xml:S2:9723:2	O
,	VICTRELIS.xml:S2:9725:1	O
and	VICTRELIS.xml:S2:9727:3	O
24	VICTRELIS.xml:S2:9731:2	O
,	VICTRELIS.xml:S2:9733:1	O
at	VICTRELIS.xml:S2:9735:2	O
the	VICTRELIS.xml:S2:9738:3	O
end	VICTRELIS.xml:S2:9742:3	O
of	VICTRELIS.xml:S2:9746:2	O
treatment	VICTRELIS.xml:S2:9749:9	O
,	VICTRELIS.xml:S2:9758:1	O
during	VICTRELIS.xml:S2:9760:6	O
treatment	VICTRELIS.xml:S2:9767:9	O
follow	VICTRELIS.xml:S2:9777:6	O
-	VICTRELIS.xml:S2:9783:1	O
up	VICTRELIS.xml:S2:9784:2	O
,	VICTRELIS.xml:S2:9786:1	O
and	VICTRELIS.xml:S2:9788:3	O
for	VICTRELIS.xml:S2:9792:3	O
other	VICTRELIS.xml:S2:9796:5	O
time	VICTRELIS.xml:S2:9802:4	O
points	VICTRELIS.xml:S2:9807:6	O
as	VICTRELIS.xml:S2:9814:2	O
clinically	VICTRELIS.xml:S2:9817:10	O
indicated	VICTRELIS.xml:S2:9828:9	O
.	VICTRELIS.xml:S2:9837:1	O

Use	VICTRELIS.xml:S2:9839:3	O
of	VICTRELIS.xml:S2:9843:2	O
a	VICTRELIS.xml:S2:9846:1	O
sensitive	VICTRELIS.xml:S2:9848:9	O
real	VICTRELIS.xml:S2:9858:4	O
-	VICTRELIS.xml:S2:9862:1	O
time	VICTRELIS.xml:S2:9863:4	O
reverse	VICTRELIS.xml:S2:9868:7	O
-	VICTRELIS.xml:S2:9875:1	O
transcription	VICTRELIS.xml:S2:9876:13	O
polymerase	VICTRELIS.xml:S2:9890:10	O
chain	VICTRELIS.xml:S2:9901:5	O
reaction	VICTRELIS.xml:S2:9907:8	O
(	VICTRELIS.xml:S2:9916:1	O
RT	VICTRELIS.xml:S2:9917:2	O
-	VICTRELIS.xml:S2:9919:1	O
PCR	VICTRELIS.xml:S2:9920:3	O
)	VICTRELIS.xml:S2:9923:1	O
assay	VICTRELIS.xml:S2:9925:5	O
for	VICTRELIS.xml:S2:9931:3	O
monitoring	VICTRELIS.xml:S2:9935:10	O
HCV	VICTRELIS.xml:S2:9946:3	O
-	VICTRELIS.xml:S2:9949:1	O
RNA	VICTRELIS.xml:S2:9950:3	O
levels	VICTRELIS.xml:S2:9954:6	O
during	VICTRELIS.xml:S2:9961:6	O
treatment	VICTRELIS.xml:S2:9968:9	O
is	VICTRELIS.xml:S2:9978:2	O
recommended	VICTRELIS.xml:S2:9981:11	O
.	VICTRELIS.xml:S2:9992:1	O

The	VICTRELIS.xml:S2:9994:3	O
assay	VICTRELIS.xml:S2:9998:5	O
should	VICTRELIS.xml:S2:10004:6	O
have	VICTRELIS.xml:S2:10011:4	O
a	VICTRELIS.xml:S2:10016:1	O
lower	VICTRELIS.xml:S2:10018:5	O
limit	VICTRELIS.xml:S2:10024:5	O
of	VICTRELIS.xml:S2:10030:2	O
HCV	VICTRELIS.xml:S2:10033:3	O
-	VICTRELIS.xml:S2:10036:1	O
RNA	VICTRELIS.xml:S2:10037:3	O
quantification	VICTRELIS.xml:S2:10041:14	O
of	VICTRELIS.xml:S2:10056:2	O
equal	VICTRELIS.xml:S2:10059:5	O
to	VICTRELIS.xml:S2:10065:2	O
or	VICTRELIS.xml:S2:10068:2	O
less	VICTRELIS.xml:S2:10071:4	O
than	VICTRELIS.xml:S2:10076:4	O
25	VICTRELIS.xml:S2:10081:2	O
IU	VICTRELIS.xml:S2:10084:2	O
per	VICTRELIS.xml:S2:10087:3	O
mL	VICTRELIS.xml:S2:10091:2	O
,	VICTRELIS.xml:S2:10093:1	O
and	VICTRELIS.xml:S2:10095:3	O
a	VICTRELIS.xml:S2:10099:1	O
limit	VICTRELIS.xml:S2:10101:5	O
of	VICTRELIS.xml:S2:10107:2	O
HCV	VICTRELIS.xml:S2:10110:3	O
-	VICTRELIS.xml:S2:10113:1	O
RNA	VICTRELIS.xml:S2:10114:3	O
detection	VICTRELIS.xml:S2:10118:9	O
of	VICTRELIS.xml:S2:10128:2	O
approximately	VICTRELIS.xml:S2:10131:13	O
10	VICTRELIS.xml:S2:10145:2	O
to	VICTRELIS.xml:S2:10148:2	O
15	VICTRELIS.xml:S2:10151:2	O
IU	VICTRELIS.xml:S2:10154:2	O
per	VICTRELIS.xml:S2:10157:3	O
mL	VICTRELIS.xml:S2:10161:2	O
.	VICTRELIS.xml:S2:10163:1	O

For	VICTRELIS.xml:S2:10165:3	O
the	VICTRELIS.xml:S2:10169:3	O
purposes	VICTRELIS.xml:S2:10173:8	O
of	VICTRELIS.xml:S2:10182:2	O
assessing	VICTRELIS.xml:S2:10185:9	O
Response	VICTRELIS.xml:S2:10195:8	O
-	VICTRELIS.xml:S2:10203:1	O
Guided	VICTRELIS.xml:S2:10204:6	O
Therapy	VICTRELIS.xml:S2:10211:7	O
milestones	VICTRELIS.xml:S2:10219:10	O
,	VICTRELIS.xml:S2:10229:1	O
a	VICTRELIS.xml:S2:10231:1	O
confirmed	VICTRELIS.xml:S2:10233:9	O
"	VICTRELIS.xml:S2:10243:1	O
detectable	VICTRELIS.xml:S2:10244:10	O
but	VICTRELIS.xml:S2:10255:3	O
below	VICTRELIS.xml:S2:10259:5	O
limit	VICTRELIS.xml:S2:10265:5	O
of	VICTRELIS.xml:S2:10271:2	O
quantification	VICTRELIS.xml:S2:10274:14	O
"	VICTRELIS.xml:S2:10288:1	O
HCV	VICTRELIS.xml:S2:10290:3	O
-	VICTRELIS.xml:S2:10293:1	O
RNA	VICTRELIS.xml:S2:10294:3	O
result	VICTRELIS.xml:S2:10298:6	O
should	VICTRELIS.xml:S2:10305:6	O
not	VICTRELIS.xml:S2:10312:3	O
be	VICTRELIS.xml:S2:10316:2	O
considered	VICTRELIS.xml:S2:10319:10	O
equivalent	VICTRELIS.xml:S2:10330:10	O
to	VICTRELIS.xml:S2:10341:2	O
an	VICTRELIS.xml:S2:10344:2	O
"	VICTRELIS.xml:S2:10347:1	O
undetectable	VICTRELIS.xml:S2:10348:12	O
"	VICTRELIS.xml:S2:10360:1	O
HCV	VICTRELIS.xml:S2:10362:3	O
-	VICTRELIS.xml:S2:10365:1	O
RNA	VICTRELIS.xml:S2:10366:3	O
result	VICTRELIS.xml:S2:10370:6	O
(	VICTRELIS.xml:S2:10377:1	O
reported	VICTRELIS.xml:S2:10378:8	O
as	VICTRELIS.xml:S2:10387:2	O
"	VICTRELIS.xml:S2:10390:1	O
Target	VICTRELIS.xml:S2:10391:6	O
Not	VICTRELIS.xml:S2:10398:3	O
Detected	VICTRELIS.xml:S2:10402:8	O
"	VICTRELIS.xml:S2:10410:1	O
or	VICTRELIS.xml:S2:10412:2	O
"	VICTRELIS.xml:S2:10415:1	O
HCV	VICTRELIS.xml:S2:10416:3	O
-	VICTRELIS.xml:S2:10419:1	O
RNA	VICTRELIS.xml:S2:10420:3	O
Not	VICTRELIS.xml:S2:10424:3	O
Detected	VICTRELIS.xml:S2:10428:8	O
"	VICTRELIS.xml:S2:10436:1	O
)	VICTRELIS.xml:S2:10437:1	O
.	VICTRELIS.xml:S2:10438:1	O

Complete	VICTRELIS.xml:S2:10444:8	O
blood	VICTRELIS.xml:S2:10453:5	O
count	VICTRELIS.xml:S2:10459:5	O
(	VICTRELIS.xml:S2:10465:1	O
with	VICTRELIS.xml:S2:10466:4	O
white	VICTRELIS.xml:S2:10471:5	O
blood	VICTRELIS.xml:S2:10477:5	O
cell	VICTRELIS.xml:S2:10483:4	O
differential	VICTRELIS.xml:S2:10488:12	O
counts	VICTRELIS.xml:S2:10501:6	O
)	VICTRELIS.xml:S2:10507:1	O
should	VICTRELIS.xml:S2:10509:6	O
be	VICTRELIS.xml:S2:10516:2	O
obtained	VICTRELIS.xml:S2:10519:8	O
at	VICTRELIS.xml:S2:10528:2	O
pretreatment	VICTRELIS.xml:S2:10531:12	O
,	VICTRELIS.xml:S2:10543:1	O
and	VICTRELIS.xml:S2:10545:3	O
at	VICTRELIS.xml:S2:10549:2	O
Treatment	VICTRELIS.xml:S2:10552:9	O
Weeks	VICTRELIS.xml:S2:10562:5	O
2	VICTRELIS.xml:S2:10568:1	O
,	VICTRELIS.xml:S2:10569:1	O
4	VICTRELIS.xml:S2:10571:1	O
,	VICTRELIS.xml:S2:10572:1	O
8	VICTRELIS.xml:S2:10574:1	O
,	VICTRELIS.xml:S2:10575:1	O
and	VICTRELIS.xml:S2:10577:3	O
12	VICTRELIS.xml:S2:10581:2	O
,	VICTRELIS.xml:S2:10583:1	O
and	VICTRELIS.xml:S2:10585:3	O
should	VICTRELIS.xml:S2:10589:6	O
be	VICTRELIS.xml:S2:10596:2	O
monitored	VICTRELIS.xml:S2:10599:9	O
closely	VICTRELIS.xml:S2:10609:7	O
at	VICTRELIS.xml:S2:10617:2	O
other	VICTRELIS.xml:S2:10620:5	O
time	VICTRELIS.xml:S2:10626:4	O
points	VICTRELIS.xml:S2:10631:6	O
,	VICTRELIS.xml:S2:10637:1	O
as	VICTRELIS.xml:S2:10639:2	O
clinically	VICTRELIS.xml:S2:10642:10	O
appropriate	VICTRELIS.xml:S2:10653:11	O
.	VICTRELIS.xml:S2:10664:1	O

Refer	VICTRELIS.xml:S2:10671:5	O
to	VICTRELIS.xml:S2:10677:2	O
the	VICTRELIS.xml:S2:10680:3	O
prescribing	VICTRELIS.xml:S2:10684:11	O
information	VICTRELIS.xml:S2:10696:11	O
for	VICTRELIS.xml:S2:10708:3	O
peginterferon	VICTRELIS.xml:S2:10712:13	O
alfa	VICTRELIS.xml:S2:10726:4	O
and	VICTRELIS.xml:S2:10731:3	O
ribavirin	VICTRELIS.xml:S2:10735:9	O
for	VICTRELIS.xml:S2:10745:3	O
pre	VICTRELIS.xml:S2:10749:3	O
-	VICTRELIS.xml:S2:10752:1	O
treatment	VICTRELIS.xml:S2:10753:9	O
,	VICTRELIS.xml:S2:10762:1	O
on	VICTRELIS.xml:S2:10764:2	O
-	VICTRELIS.xml:S2:10766:1	O
treatment	VICTRELIS.xml:S2:10767:9	O
and	VICTRELIS.xml:S2:10777:3	O
post	VICTRELIS.xml:S2:10781:4	O
-	VICTRELIS.xml:S2:10785:1	O
treatment	VICTRELIS.xml:S2:10786:9	O
laboratory	VICTRELIS.xml:S2:10796:10	O
testing	VICTRELIS.xml:S2:10807:7	O
recommendations	VICTRELIS.xml:S2:10815:15	O
including	VICTRELIS.xml:S2:10831:9	O
hematology	VICTRELIS.xml:S2:10841:10	O
,	VICTRELIS.xml:S2:10851:1	O
biochemistry	VICTRELIS.xml:S2:10853:12	O
(	VICTRELIS.xml:S2:10866:1	O
including	VICTRELIS.xml:S2:10867:9	O
hepatic	VICTRELIS.xml:S2:10877:7	O
function	VICTRELIS.xml:S2:10885:8	O
tests	VICTRELIS.xml:S2:10894:5	O
)	VICTRELIS.xml:S2:10899:1	O
,	VICTRELIS.xml:S2:10900:1	O
and	VICTRELIS.xml:S2:10902:3	O
pregnancy	VICTRELIS.xml:S2:10906:9	O
testing	VICTRELIS.xml:S2:10916:7	O
requirements	VICTRELIS.xml:S2:10924:12	O
.	VICTRELIS.xml:S2:10936:1	O
